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2.  Abbreviations 
ALS .............................................................................................................................. amyotrophic lateral sclerosis 
APOA2 ......................................................................................................................................... apolipoprotein A-II 
BSA ........................................................................................................................................ bovine serum albumin 
C. Elegans .......................................................................................................................... Caenorhabditis elegans 
C9ORF72 ..................................................................................................... chromosome 9 open reading frame 72 
CaCl2 ............................................................................................................................................... calcium chloride 
CDK6 ............................................................................................................................... cyclin-dependent kinase 6 
cDNA ........................................................................................................................................ complementary DNA 
CFTR .................................................................................... cystic fibrosis transmembrane conductance regulator 
CHMP2B ...................................................................................................... charged multivesicular body protein 2b 
CTF ............................................................................................................................................ C terminal fragment 
DAB ........................................................................................................................................ 3,3'-Diaminobenzidine 
DLB ................................................................................................................................ dementia with Lewy bodies 
DNA ........................................................................................................................................ deoxyribonucleic acid 
EDNRB .......................................................................................................................... endothelin receptor, type B 
EDTA ...................................................................................................................... ethylenediaminetetraacetic acid 
ENS ...................................................................................................................................... enteric nervous system 
fALS ................................................................................................................. familial amyotrophic lateral sclerosis 
FBS .............................................................................................................................................. fetal bovine serum 
FTD .............................................................................................................................. frontotemporal degeneration 
FTLD ...........................................................................................................................frontotemporal lobe dementia 
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FTLD-U ........................................................................................................ FTLD with ubiquitin-positive inclusions 
FUS ......................................................................................................... fused in sarcoma/translocated in sarcoma 
GDNF ................................................................................................................ glial cell-derived neurotrophic factor 
GRN ............................................................................................................................................................. granulin 
H&E ....................................................................................................................................... hematoxylin and eosin 
HCL ................................................................................................................................................ hydrochloric acid 
HDAC6 ................................................................................................................................... histone deacetylase 6 
Hepes ........................................................................................ 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HITS-CLIP ..................................high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation 
hnRNP ..................................................................................................... heterogeneous nuclear ribonucleoprotein 
HRP ..................................................................................................................................... horseradish peroxidase 
hTDP-43 ............................................................................................................................................ human TDP-43 
ICC ........................................................................................................................................ interstitial cells of Cajal 
IF  ............................................................................................................................................ immunofluorescence 
IHC ........................................................................................................................................ immunohistochemistry 
KCl .............................................................................................................................................. potassium chloride 
kDa ............................................................................................................................................................. kilodalton 
KH2PO4 .................................................................. monopotassium phosphate / potassium dihydrogen phosphate 
M  ...........................................................................................................................................................molar mass 
MAP1B ................................................................................................................ microtubule-associated protein 1B 
MAPT ................................................................................................................. microtubule-associated protein tau  
MgCl2 ........................................................................................................................................ magnesium chloride 
miRNA ....................................................................................................................................................... microRNA 
mRNA ................................................................................................................. messenger RNA, messenger RNA 
NaCl ................................................................................................................................................. sodium chloride 
NES ....................................................................................................... nuclear export signal, nuclear export signal 
NLS ........................................................................................ nuclear localization signal, nuclear localization signal 
Nonidet P-40 ........................................................................................................... octylphenoxypolyethoxyethanol 
OMPA .................................................................................................................. tetraisopropylpyrophosphoramide 
OPTN ........................................................................................................................................................ optineurin 
p  ................................................................................................................................................................. p-value 
PaGE ........................................................................................................................................ Paw grip endurance 
PBS .................................................................................................................................. phosphate buffered saline 
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PCR ................................................................................................................................ polymerase chain reaction 
PFN1 ........................................................................................................................................................... profilin-1 
PGC-1α ....................................................... peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
PMSF ........................................................................................................................ phenylmethanesulfonylfluoride 
PrP ......................................................................................................................................... prion protein promotor 
PVDF ..................................................................................................................................... polyvinylidene fluoride 
RET ........................................................................................................................... rearranged during transfection 
RIPA ....................................................................................................................... radio immunoprecipitation assay 
RNA ................................................................................................................................................. ribonucleic acid 
RRM ....................................................................................................................................... RNA recognition motif 
sALS ............................................................................................................. sporadic amyotrophic lateral sclerosis 
SC35 ................................................................................................................. serine/arginine-rich splicing factor 2 
SD ................................................................................................................................................ standard deviation 
SDS ....................................................................................................................................... sodium dodecyl sulfate 
SDS–PAGE ................................................................ sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM ...................................................................................................................................... standard error of mean 
SG ....................................................................................................................................................... stress granule 
SMN .................................................................................................................................... survival of motor neuron 
SNP ......................................................................................................................... single nucleotide polymorphism 
SOD1 .................................................................................................................................. superoxide dismutase 1 
SQSTM1 ......................................................................................................................................... sequestosome-1 
TAR ......................................................................................................................... transactivation response region 
TARDBP ......................................................................... transactive response DNA binding protein 43 kDa (gene) 
tardbpl ........................................................................................................................ TAR DNA binding protein, like 
TDP-43 ................................................................................................... TAR DNA-binding protein 43 kDA (protein) 
Tris ...................................................................................................................... tris(hydroxymethyl)aminomethane 
TSE buffer .......................................................................................................................... tris sucrose EDTA buffer 
UBQLN2 .................................................................................................................................................... ubiquilin-2 
UTR ............................................................................................................................................ untranslated region 
UV .............................................................................................................................................................. ultraviolet 
VCP .................................................................................................................................. valosin-containing protein  
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3. Summary 
Amyotrophic lateral sclerosis (ALS) is the most frequent form of motor neuron 
disease and the third most common neurodegenerative disease after Alzheimer and 
Parkinson with an estimated incidence of 2.6/100.000 per annum. It is characterized 
by a loss of motor neurons in the brain and spinal cord leading to a fatal paralysis 
and death within 1 to 5 years. During the last years, it became clear that ALS is a 
clinical manifestation of genetic disorders in various genes, affecting multiple cellular 
pathways and leading to heterogeneous disease pattern. Most incidences of ALS are 
sporadic (sALS) but approximately 10 percent of patients have a family history 
(fALS) of the disease. Mutations in the TARDBP gene have been identified in about 
four percent of fALS and less than one percent of sALS, though TDP-43 pathology is 
a consistent feature in all sALS cases and the majority of fALS cases. TDP-43 
pathology is characterized by aberrant cytoplasmic TDP-43 inclusions with distinct 
nuclear clearance in effected neurons, accompanied by a protein truncation, 
ubiquitination and hyperphosphorylation. However, the functional consequences of 
TDP-43 mutations triggering the disease remain unknown. Strikingly, pathological 
TDP-43 aggregates are also reported for ~50% patients with of frontotemporal 
degeneration (FTD), including most of the patients who develop FTD in combination 
with amyotrophic lateral sclerosis. 
In order to unravel the pathomechanisms underlying TDP-proteinopathies, we 
generated and analysed TDP-43 transgenic animals expressing four different 
constructs covering overexpression of wild type human TDP-43, the ALS-related 
mutations M337V and G348C as well as an altered nuclear localization signal, 
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inducing cytoplasmic translocation with comparable expression levels. We could 
demonstrate that expression of TDP-43 species with human pathogenic mutations or 
forced cytoplasmic mislocalization of TDP-43 do not per se induce disease-related 
phenotypes in our transgenic lines. This argues against a toxic gain-of-function 
mechanism of human pathogenic mutations and increased levels of cytoplasmic 
TDP-43. 
Animals of our wild type line (hTDP-43 WT-7) line showed a pathological phenotype, 
as they die premature after 3 to 6 months from a gut phenotype, resulting from a 
dilated ileum and colon. This is accompanied by a decreased number of ganglion 
cells in the Auerbach´s plexus (myenteric plexus) of the colon. WT-7 animals 
showed no motoric constraint or pathological changes in the CNS, speaking for a 
detrimental effect of TDP-43 overexpression with the enteric nervous system being 
the most vulnerable cell population. Remarkably, the observed phenotype was not 
associated with pathological inclusions. 
Furthermore, we noticed a high gender discrepancy of the life span with an earlier 
onset in hTDP-43 WT-7 males. We were able to abolish this difference by 
ovariectomy of hTDP-43 WT-7 females and administration of 17β-estradiol to 
ovariectomized females resulted in a partial extension of the life span, thus indicating 
a beneficial effect of female sex hormones in TDP-43 mediated toxicity, suggesting 
potential for future treatment in human TDP-43 proteinopathies. 
In summary, we could demonstrate that comparable levels of human wild type 
TDP-43 is more toxic in vivo compared to human pathogenic mutations and 
cytoplasmic TDP-43. While the hTDP-43 WT-7 mice do not reflect characteristical 
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histological features of human TDP-43 proteinopathies, they will be valuable tools to 
further dissect the role of TDP-43 in neurons. 
4. Zusammenfassung 
Amyotrophe Lateralsklerose (ALS) ist die häufigste neurodegenerative Erkrankung 
des motorischen Nervensystems und die dritthäufigste neurodegenerative 
Erkrankung nach Alzheimer und Parkinson, mit einer geschätzten Inzidenz von 
2.6/100.000. Sie ist  durch einen Verlust der motorischen Nervenzellen in Gehirn und 
Rückenmark gekennzeichnet, der innerhalb von 1 bis 5 Jahren nach Diagnose zum 
Tod durch Atemlähmung führt. Forschungen der letzten Jahre haben gezeigt, dass 
ALS von Mutationen in verschiedenen Genen hervorgerufen werden kann. Die 
entsprechenden Proteine sind an unterschiedlichen zellulären Prozessen beteiligt, 
so dass ALS, auch aufgrund der heterogenen Krankheitsausprägung, eher als 
klinische Manifestation unterschiedlicher Proteinopathien verstanden werden kann. 
Zumeist tritt ALS als sporadische Erkrankung (sALS) auf; aber etwa 10 Prozent der 
Fälle sind auf vererbte Genveränderungen zurückzuführen (fALS). Mutationen im 
Gen TARDBP wurden in etwa vier Prozent der fALS-Patienten und weniger als ein 
Prozent der sALS-Patienten als Krankheitsursache identifiziert. TDP-43 Pathologie 
ist jedoch in allen bisher beschriebenen sALS Fällen und dem überwiegenden Teil 
der fALS Fälle beobachtet worden. Merkmale der TDP-43 Pathologie sind die 
Bildung von Proteinaggregaten im Zytoplasma betroffener Neuronen und das 
Auftreten verkürzter, ubiquitinierter und hyperphosphorylierter TDP-43 Proteine. Die 
genauen funktionellen Veränderungen durch TDP-43 Mutationen und ihr Beitrag zur 
Pathogenese sind allerdings unklar. Pathologische TDP-43-Aggregate finden sich 
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interessanterweise auch in ~50 % der Fälle von Frontotemporaler Degeneration 
(FTD), unter ihnen auch ein Großteil der Patienten mit einer überschneidenden ALS-
Diagnose.  
Zur Aufklärung der zugrundeliegenden Pathomechanismen bei TDP-43 
Proteinopathien haben wir transgene Mäuse generiert und untersucht, die vier 
verschiedene TDP-43 Konstrukte mit annährend gleichem Proteinlevel exprimieren. 
Dazu gehört die Überexpression des humanen Wildtyp TDP-43, humanes TDP-43 
mit den ALS-auslösenden Mutationen M337V bzw. G348C sowie humanes TDP-43 
mit einem veränderten Kernlokalisierungssignal zur erzwungenen zytoplasmatischen 
Translokation. Wir konnten zeigen, dass die alleinige Expression von TDP-43 mit 
humanpathogenen Mutationen oder die Lokalisation von TDP-43 im Zytoplasma in 
unseren transgenen Linien nicht ausreicht um einen krankheitsassoziierten 
Phänotyp hervorzurufen. Diese Ergebnisse sprechen gegen einen Gain-of-function 
Mechanismus durch humanpathogene Mutationen oder erhöhte zytoplasmatische 
TDP-43 Level. 
Mäuse der Linie hTDP-43 WT-7, die den humanen Wildtyp überexprimiert, zeigen 
einen pathologischen Phänotyp: innerhalb eines Zeitraums von 3 bis 6 Monaten 
versterben sie auf Grund einer gastrointestinalen Mobilitätsstörung, charakterisiert 
durch eine Erweiterung von Ileum und Colon. Dies geht einher mit einer Reduktion 
der Ganglienzellen im  Auerbach Plexus des Colon (myenterischer Plexus). Im 
Gegensatz dazu zeigen hTDP-43 WT-7 Mäuse auch kurz vor dem Tod keine 
motorischen Einschränkungen oder pathologische Veränderungen im ZNS. Dies 
deutet auf einen negativen Effekt der TDP-43 Überexpression hin, der auf besonders 
anfällige Zellpopulationen im enterischen Nervensystem begrenzt ist. 
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Wir konnten darüber hinaus bei WT-7 Weibchen eine signifikant höhere 
Lebenserwartung im Vergleich zu Männchen beobachten. Das Entfernen der 
Eierstöcke reduzierte die Lebenserwartung der Weibchen, während die Gabe von 
17β-estradiol an kastrierte Weibchen zu einer partiellen Lebensverlängerung führte, 
was für einen positiven Effekt weiblicher Geschlechtshormone spricht und das  
Potential für zukünftige Therapien humaner TDP-43 Proteinopathien aufzeigt. 
Zusammenfassend können wir schlussfolgern, dass humanes Wildtyp TDP-43 in 
vivo toxischer ist als ein vergleichbares Level von TDP-43 mit humanpathogenen 
Mutationen oder zytoplasmatischem TDP-43. Obwohl die hTDP-43 WT-7 Mauslinie 
nicht die histologischen Charakteristika humaner TDP-43 Proteinopathien zeigt, 
kann sie doch in Zukunft ein wichtiges Modell zur Aufklärung der generellen Funktion 
von TDP-43 in Neuronen sein. 
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5. Introduction 
5.1. TDP-43, a key player in the pathology of amyotrophic lateral sclerosis and 
frontotemporal lobar degeneration 
Over the last decade, there has been growing evidence that two formerly unrelated 
neurodegenerative diseases show a clinical overlap and share genetically and 
pathological similarities. 
Frontotemporal lobar degeneration (FTLD) is the second most common type of 
dementia after Alzheimer’s disease in patients less than 65 years of age with an 
estimated prevalence of 15 per 100.000 and tends to occur at a younger age 
compared to Alzheimer's disease [1, 2]. FTLD represents a group of different 
disorders, characterized by atrophy in the frontal and temporal lobe of the human 
brain with neuronal loss and astrocytosis. Personality, behaviour and language can 
change in various degrees, resulting in a clinical syndrome called frontotemporal 
dementia (FTD), which is further subdivided by distinctive clinical impairments, 
determined through differences in the affected brain regions. Approximately 10% to 
30% of FTLD cases have an autosomal dominant pattern of inheritance, indicating a 
significant genetic influence [3]. Currently, there are six genes known carrying 
mutations linked to FTLD:  MAPT, GRN and C9ORF72 have emerged as common 
FTLD genes, whereas TARDBP, VCP, FUS, and CHMP2B have been identified as 
rare genetic causes [4]. 
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Amyotrophic lateral sclerosis is the most frequent form of motor neuron disease and 
the third most common neurodegenerative disease after Alzheimer´s disease and 
Parkinson´s disease with an estimated incidence of 2.6 per 100.000 [5]. It is 
characterized by a loss of motor neurons in the brain and spinal cord leading to a 
fatal paralysis and death within 1 to 5 years [6]. The famous French neurologist 
Jean-Martin Charcot initially described it in the year 1869, discovering that lesions 
within the lateral column in the spinal cord resulted in chronic progressive paralysis 
and contractures (without atrophy of muscles), while lesions of the anterior horn of 
the spinal cord resulted in paralysis without contractures (with atrophy of muscles). 
He recognized that the motor component of the spinal cord consists of a two-part 
system, and that the location of the lesion results in a varying clinical presentation 
[7]. Comorbidity of ALS and FTLD symptoms is estimated to occur in roughly 50% of 
the patients [8-11]. ALS can be split into two groups: sporadic ALS (sALS) accounts 
for 90-95% of ALS cases, with patients having no family history of ALS and familial 
ALS (fALS) with a hereditary pattern. Currently, the genetic etiology of two-thirds of 
fALS cases and about 11% of sALS cases is known [12] caused by mutations in 
eight confirmed ALS-associated genes: SOD1, TARDBP, FUS, OPTN, SQSTM1, 
VCP, UBQLN2, C9ORF72 and PFN1 [13-22]. sALS and fALS are clinically similar, 
but clinical comparison of the various fALS associated genes showed differences in 
site of onset (predominantly lower limbs for SOD1 and upper limbs for TARDBP 
mutations), age of onset (younger with FUS mutations), and in lifespan (shorter for 
FUS carriers) [23]. However, the clinical phenotype varies greatly, e.g. a difference in 
disease onset of more than 30 years within a family and duration of illness varying 
from 6 months to 5 years [24]. 
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The detection of differently shaped ubiquitinated protein aggregates in sporadic and 
familiar ALS in the early 1990s was a major finding, speaking for accumulations of 
altered or abnormal neuronal proteins resistant to degradation via the ubiquitin 
proteolytic pathway [25, 26]. Likewise, the most common neuropathological subtype 
of FTD has been characterized by ubiquitin-positive but tau- and α-synuclein-
negative inclusions and was therefore named Frontotemporal lobar degeneration 
with ubiquitin-positive inclusions (FTLD-U) [27]. However, the ubiquitinated protein(s) 
itself remained unknown. 
In 2006, TAR DNA-binding protein 43 (TDP-43) was described as the principal 
component of the ubiquitinated inclusions in the vast majority of FTLD and ALS 
cases [14], now labelled as FTLD-TDP and ALS-TDP [28]. The discovery of TDP-43 
as a pathological protein set a genetic link between ALS and FTLD. TDP-43 
pathology is present in almost all patients with FTD associated with ALS, in a 
significant proportion of FTD patients without overt motor neuron disease and in 
most patients with sporadic and familial ALS. The distribution of TDP-43 pathology 
tends to correlate with brain areas of atrophy, the stage of dementia and motor 
impairments in FTLD and ALS, allowing a further subtyping of FTLD-TDP by 
pathological characteristics of TDP-43 [29, 30]. In ALS, pathological TDP-43 is 
mainly present pyramidal motor system, but is also observed in multiple brain areas 
to a variable extent [31]. 
The discovered clinical and pathological similarities between most cases of FTLD 
and ALS resulted in major rearrangements in the pathological classification system. 
FTLD-U and ALS with ubiquitin-positive inclusions are now reclassified under the 
umbrella term TDP-43 proteinopathies, covering a group of disorders exhibiting 
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heterogeneous clinical phenotypes [28]. The distribution of TDP-43 pathology tends 
to correlate with brain areas of atrophy, the stage of dementia and motor 
impairments in FTLD and ALS, allowing a further subtyping of FTLD-TDP by 
pathological characteristics [29, 30]. In ALS, pathological TDP-43 is mainly present 
pyramidal motor system, but is also observed in multiple brain areas to a variable 
extent [31]. 
Interestingly, TDP-43 inclusions were absent in patients affected by gene mutations 
in the first discovered ALS-associated gene, SOD1, speaking for a different 
molecular mechanism [32]. This is an important finding as many scientists used 
SOD1 animals as a model for amyotrophic lateral sclerosis. 
Under normal conditions, TDP-43 is mainly localized to the nucleus, but neurons with 
aberrant cytoplasmic TDP-43 inclusions in FTLD-TDP and ALS-TDP show a distinct 
nuclear clearance, accompanied by protein truncation and hyperphosphorylation [14, 
33]. Plenty of causative mutations in TARDBP, the gene encoding TDP-43, were 
reported in patients with either ALS-TDP or FTLD-TDP, indicating a direct link 
between mutations in TADBP and disease [15, 34-36]. Some of these mutations like 
M337V and G348C are inherited following an autosomal dominant trait of inheritance 
and can be traced throughout unrelated fALS families, supporting the assumption of 
an autosomal dominant trait [34, 37-39]. However, only a small minority of 4% of 
fALS patients, an even smaller number of sALS patients and rare cases of FTLD 
carry coding mutations in the TARDBP gene, while the vast majority of ALS-TDP and 
FTLD-TDP cases occur in the absence of TARDBP mutations [40, 41]. Aggregation 
and nuclear depletion of wild type TDP-43 is a constant feature associated with 
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mutations in other genes like GRN and VCP and the newly found C9orf72 
hexanucleotide expansion [4, 12]. 
Remarkably, pathological TDP-43 aggregations are not restricted to FTLD-TDP and 
ALS-TDP: secondary TDP-43 accumulations occur also in multiple other 
neurodegenerative disorders and were even infrequently reported for brains of 
control subjects over 65 years without mental retardation [1, 42, 43]. TDP-43 
pathology is detected in 25% to 50% of AD cases with a higher probability in those 
with more a severe clinical phenotype and greater Alzheimer type pathology [44]. 
Some patients with Lewy body disorders also develop TDP-43 pathology, with 
estimated 7.2% in Parkinson’s disease without dementia and 19% in Parkinson’s 
disease with dementia, while dementia with Lewy bodies exhibited no TDP-43 
pathology [45]. These data suggest that TDP-43 pathology may have co-morbid 
effects in some neurodegenerative diseases.  
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Figure 1. Pathological features in ALS-TDP and FTLD-TDP. TDP-43 
immunohistochemistry on paraffin-embedded tissue showing (A) TDP-43-immunoreactive 
skein-like and (B) round inclusions in motor neurons in ALS-TDP. FTLD-TDP pathology is 
subdivided into four distinct morphological subtypes: (C) type 1 is characterized by compact 
neuronal cytoplasmic inclusions and short neurites; (D) type 2 is characterized by long 
neurites; (E) type 3 is characterized by compact and granular cytoplasmic inclusions; and (F) 
type 4 is characterized by numerous neuronal intranuclear inclusions. (G) Cytoplasmic 
inclusions in the dentate granule cells of the hippocampus. Nuclear staining is absent in 
inclusion-bearing cells. (H) Glial cytoplasmic inclusions. Scale bars: 40 µm (D), 20 µm (A, C, 
G), 15 µm (E, F), and 10 µm (B, H). (I) Immunoblot analysis of urea fractions isolated from 
brain tissue, showing the highly characteristic biochemical signature of TDP-43 in 
FTLD-TDP, with pathological bands of approximately 25 kDa (*) and 45 kDa (**), and a high-
molecular-weight smear (***) that are not detected in controls. The arrow indicates the wild-
type 43 kDa TDP-43 band present in controls and in patients with FTLD-TDP. Notably, only 
pathological TDP-43 is detected by a phosphorylation-specific TDP-43 antibody against 
phosphorylated serine residues 409 and 410. (from Mackenzie et al. 2010, [28]) 
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5.2. Protein structure and functions of TDP-43 
Since its first description, TDP-43 has not attracted much attention in the scientific 
community for a decade. In 1995, Ou et al. characterized a novel transcriptional 
repressor binding chromosomally integrated TAR DNA and repressing HIV-1 
transcription. They named it TAR DNA-binding protein 43 (TDP-43) [46]. Six years 
later Buratti et al. identified TDP-43 as the factor binding specifically to the splice 
sites in the cystic fibrosis transmembrane conductance regulator (CFTR), promoting 
exon skipping at exon 9. This was the first description of RNA binding by TDP-43 
and its relevance for pre-mRNA splicing [47]. Similar observations were reported for 
the apolipoprotein A-II (APOA2) transcript, survival of motor neuron (SMN) and 
serine/arginine-rich splicing factor 2 (SC35) [48-50]. After identification of TDP-43 as 
a pathological protein in ALS and FTLD in 2006 great efforts were made to 
understand physiological functions and structural determinants of TDP-43. 
TDP-43 is a highly conserved member of the hnRNP protein family with a nuclear 
localization signal at the N-terminus, two RNA recognition motifs named RRM1 and 
RRM2, later bearing a nuclear export signal [51]. Both RRMs have the ability to bind 
nucleic acids but only RRM1 appears to be essential for RNA splicing [47]. TDP-43 
preferentially binds UG repeats, but is also found to be associated with non-UG 
repeat sequences [47, 52, 53]. High-throughput sequencing of RNA isolated by 
crosslinking immunoprecipitation (HITS-CLIP) showed that TDP43 binds to a large 
proportion of the transcriptome (more than 6,000 RNA species), preferentially 
localizing to introns (including deep intronic sites), 3′ untranslated regions (UTRs) 
and non-coding RNAs [54, 55]. Functional classification of TDP-43 RNA targets from 
cortical neurons revealed a significant number of targets related to neuronal 
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development and axon guidance [56]. Furthermore, TDP-43 is a component of 
neuronal mRNA transport granules and supports trafficking of its mRNA targets to 
neuronal distal compartments [57]. 
TDP-43 acts as part of multiprotein-RNA complexes, binding both RNA and protein 
partners of the hnRNP family including hnRNP A2/B1, hnRNP A1, hnRNP C1/C2 
and hnRNP A3  [56, 58-62]. The glycine-rich C-terminal domain mediates protein-
protein interactions and contains most of the disease causing mutations. It has also 
properties of a Q/N-rich ‘prion domain’ similar to those observed in yeast prions [63, 
64].. Recent studies indicated prion-like properties of TDP-43 with intracellular 
TDP-43 exhibiting seed-dependent and self-templating aggregation [65], although 
there are conflicting results about amyloidic properties of TDP-43 aggregates [66-
68]. The results of Nonanka et al. also suggest the possibility that exosome may 
contribute to the release of intracellular TDP-43 aggregates, allowing cell-to-cell 
transmission of aberrant TDP-43 species [69]. TDP-43 self-aggregation is supposed 
to be regulated by chaperone availability [70]. However, both the N-terminus and the 
two RNA-recognition motifs have been implicated in regulating inclusion formation, 
suggesting an additional effect of RNA binding on the pathogenesis [71-75]. 
Additionally, TDP-43 species can form homodimers mediated by the N-terminus [76] 
TDP-43 is a splice regulator, but it also influences the mRNA levels of various genes: 
TDP-43 depletion increases the levels of cyclin-dependent kinase 6 (CDK6) and 
reduces the levels of Futsch (the Drosophila melanogaster homologue of 
microtubule-associated protein 1B (MAP1B)) and histone deacetylase 6 (HDAC6) 
[77-79]. 
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Figure 2. TDP-43 protein structure and mutations in ALS and FTLD patients. Thirty-
eight dominant mutations have been identified in TDP-43 in sporadic and familial ALS 
patients and in rare FTLD patients, with most lying in the C-terminal glycine-rich region. All 
are missense mutations, except for the truncating mutation TDP-43 Y374X. NLS: nuclear 
localization signal; NES: nuclear export signal. Domains have been defined according to 
http://www.uniprot.org and http://www.cbs.dtu.dk/services/NetNES. (from Lagier-Tourenne et 
al. 2010, [40]) 
Intriguingly, HDAC6 is a critical component of stress granules (SG) involved in the 
stress response, mediating the motor-protein-driven movement of individual SG 
components along microtubules [80]. SGs are cytoplasmic RNA-protein complexes, 
which temporarily assemble in response to stress-induced translational arrest [81]. 
Together with other members of the hnRNP family, TDP-43 can become part of SGs, 
where it contributes to both the assembly and maintenance of SGs [82]. 
TDP-43 also regulates microRNA (miRNA) biogenesis, as it localizes to the 
perichromatin fibres in which miRNA biogenesis is thought to occur, becoming part 
of the primary miRNA processing Drosha complex [83]. Consequently, knockdown of 
TDP43 alters the level of several miRNAs [59, 84-86]. 
Due to its diverse functions in different RNA-processing steps TDP-43 expression 
levels are tightly controlled by an autoregulatory feedback mechanism, preventing 
TDP-43 expression by a nuclear retention mechanism after TDP-43 binding to its 
own 3′ untranslated region (UTR) [87]. 
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Normal TDP-43 shows a predominantly nuclear localization, but continuously 
shuttles between nucleus and cytoplasm in a transcription-dependent manner, 
mediated by its nuclear localization signal and nuclear export signal [51]. 
5.3. Evidence for a loss-of-function mechanisms in TDP-43 proteinopathies 
The nuclear clearance of TDP-43 observed in inclusion bearing cells in FTLD and 
ALS patients argues a loss-of-function mechanism due to protein mislocalization with 
subsequent alterations at the level of gene transcription, pre-mRNA splicing, 
microRNA production, mRNA stability and mRNA translation (Figure 3). 
In support of this, knockout approaches in rodents had been lethal in early 
embryonic stage and targeted depletion of murine TDP-43 in spinal cord resulted in 
an ALS-like phenotype [88] [89]. Consistently, knockout of TDP-43 in mouse 
postnatal motor neurons using the inducible Cre/loxp system resulted in progressive 
weight loss and motor impairment accompanied by neuropathological alterations 
[90]. However, another study using mice with a conditional knockout of TDP-43 
reported a significant loss of body weight but without significant FTLD/ALS 
symptoms [91]. A modest knockdown of TDP-43 protein in the periphery and the 
central nervous system of mice is sufficient to induce progressive neurological 
phenotypes [92]. Knockdown of TDP-43 in mice also results in a large change in 
gene expression pattern, probably linked to neurodegeneration [54, 55]. This notion 
is supported by experiments where TDP-43 knockdown causes morphological 
abnormalities and cell death in cultured neurons [93-95]. 
Most TDP-43 knockout non-mammalian models did not cause embryonic lethality. 
C. Elegans TDP-43 deletion mutants are viable, but exhibit a low fertility, slow growth 
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and locomotor defects [96]. TDP-43 loss-of-function models of Drosophila show a 
high mortality in the embryonic stage such that few survive into the adult stage. 
Surviving knockout Drosophilae developed severe motor dysfunction in adulthood 
similar to those in ALS, potentially linked to alterations in motor neurons 
development [79, 97-99]. In zebrafish, two TDP-43 homologs were identified: 
loss-of-function mutants for either tardbp or tardbpl gene resulted in motor 
dysfunction [100] [101]. However, in another report, only doubly knocked-out genes 
resulted in muscle degeneration and significant motor deficits in zebrafish [102]. 
Disease-related mutations are mainly localized in the C-terminal glycine-rich region 
which is important for protein-protein interactions. Whether mutations are pathogenic 
by disruption of normal interactions is not known, but recent studies revealed 
functional deficits directly linked to TDP-43 mutations. Arnold et al. reported 
enhanced activity of mutant TDP-43 for facilitating splicing of some RNA targets, but 
“loss-of-function” for others in a transgenic mouse model overexpressing TDP-43 
with a Q331K mutation, uniquely dependent on the mutation [103]. ALS-causing 
mutations in TARDBP also impair the axonal mRNA transport in mRNA granules 
containing mutant TDP-43 protein both in in vivo models as well as in stem cell-
derived motor neurons from ALS patients bearing different TDP-43 mutations [57]. 
Interestingly, other studies showed no alteration in the direct protein-protein 
interactions by TDP-43 with pathogenic mutations [58, 60, 62]. Likewise, the 
autoregulatory properties of mutant TDP-43 remains unchanged despite FTLD or 
ALS-associated mutations, demonstrated by various transgenic mouse models [104-
106]. D169G, the only ALS-linked TDP-43 mutation identified that lies in the RRM1, 
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binds RNA- and DNA-binding as effective as wild type TDP-43, but it is more 
resistant to thermal denaturation [107, 108].  
5.4. Evidence for gain-of-function mechanisms in TDP-43 proteinopathies 
In the disease state, pathological TDP-43 is not just redistributed to the cytoplasm 
but it is also ubiquitinated, cleaved and phosphorylated and forms insoluble 
cytoplasmic aggregates. A hypothesis says that these aggregates might exhibit a 
toxic gain-of-function mechanism. (Figure 3). 
The consequences of cytoplasmic redistribution of TDP-43 were addressed by in 
vitro and in vivo studies using TDP-43 with a modified NLS-sequence, resulting in an 
impaired nuclear uptake. In 2008, Winton et al. showed in different cell culture 
models that expression of mutant TDP-43 with defective nuclear localization signals 
perturbs endogenous TDP-43 trafficking and aggregate formation in neuronal 
perikarya and neurites [109]. Increased cytoplasmic TDP-43 is toxic in primary 
cortical neurons unrelated to aggregate formation. Remarkably, Barmada et al. also 
reported an increased cytoplasmic mislocalization for the TDP-43 A315T mutant 
resulting in a decreased survival [110]. Overexpression of either human TDP-43 with 
modified NLS or the human wild type TDP-43 in mice led to neuron loss in 
selectively vulnerable forebrain regions, corticospinal tract degeneration, and motor 
spasticity recapitulating FTLD and ALS features [111]. Expression of human TDP-43 
with modified NLS in the CNS of rats by an adeno-associated virus gene transfer 
method resulted in motor impairments, but did not induce mortality [112]. 
Mislocalization of exogenous TDP-43 results in a degenerative phenotype in the 
Drosophila eye, whereas eyes of flies expressing normal TDP-43 appear 
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morphological normal [113]. However, both nuclear and cytoplasmic accumulations 
of TDP-43 in adult neurons lead to reduction of lifespan in Drosophila, accompanied 
by an abnormal phosphorylation on the disease-specific Ser409/Ser410 site [114]. 
Overexpression of TDP-43 with a mutated NLS induced degenerative phenotypes in 
most of the model systems unrelated to TDP-43 aggregate formation. 
Pathological C-terminal fragments of TDP-43 (CTFs) are a key feature of TDP-43 
proteinopathies with the potential for a gain-of-function mechanism. Expression of 
CTFs in cell culture resulted in cytoplasmic aggregates that are ubiquitinated and 
abnormally phosphorylated and splicing abnormalities [115]. Furthermore both N- 
and C-terminal fragments were prone to aggregate in cultured neurons and may 
impair neuronal differentiation by dominant-negatively interfering with the function of 
the full length TDP-43 [93]. Expression of 25 kDa C-terminal proaggregatory 
fragment of TDP-43 in mice resulted in a pronounced forelimb impairment compared 
to TDP-43 with NLS mutation [112], whereas TDP-43 CTFs expression in Drosophila 
is less severe than TDP-43 with NLS mutation or wild type TDP-43 expression [74]. 
In a majority of animal model systems, overexpression of both TDP-43 with disease-
associated mutations and wild type TDP-43 leads to a neurodegenerative phenotype 
[104-106, 116-119]. However, these models only partially recapitulate key features of 
TDP-43 proteinopathies: wild type and mutant TDP-43 is diffusely distributed in the 
cytoplasm of neuronal cells of the CNS, sometimes accompanied by nuclear and 
cytoplasmic TDP-43 inclusions, phosphorylated TDP-43 and increased ubiquitin 
staining. Some models also develop motor deficits and cognitive impairments 
correlating with the general TDP-43 protein levels. The toxic potential of mutated 
TDP-43 remains unknown, as differences in the expression strength account for 
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observed phenotypical alterations. The previous studies suggest that TDP-43 
aggregation and hyperphosphorylation are associated with the cell death process 
rather than being a direct cause, supported by experiments showing that blocked 
TDP-43 aggregation does not prevent its cytotoxicity [120]. 
While TDP-43 is evidently a stress responsive protein, it is not clear whether 
pathological TDP-43 inclusions arise from SGs, but sALS motor neurons clearly 
show a colocalization of TDP-43 positive inclusions with SG markers [121-123]. 
Furthermore, TDP-43 appears to be a crucial player in stress granule dynamics as 
TDP-43 mutations were linked to a loss-of-function mechanism in the SGs assembly 
and disassembly [82, 124]. Accordingly, disease-linked mutations increased TDP-43 
stress granule assembly in the presence of sodium arsenite [122]. These mutations 
are all localized in the Q/N-rich region, mediating protein-protein interactions. A 
repeat extension of the wild type Q/N-rich region results in an increased aggregate 
formation [125]. 
There are strong arguments for a loss-of-function as well as a gain-of-function 
mechanism, but most likely they cannot be seen as independent, single events and a 
combination of disease mechanisms might be involved. A hot topic currently under 
debate is the so-called “two-hit” or “multiple-hit” hypothesis. It assumes that TDP-43 
proteinopathies depend on cascade of cellular events starting with cytoplasmic 
mislocalization and an independent hit inducing the formation of cytoplasmic 
aggregates that may sequester TDP-43, disrupt RNA processing and initiate neuron 
degeneration. These secondary hits can include different forms of cellular stress or 
genetic risk factors, finally leading to ALS and FTLD pathology [126, 127]. 
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Figure 3: Mechanisms 
of TDP-43 mediated 
neurodegeneration. The 
upper diagrams show a 
schematic representation 
of the TDP-43 protein 
structure reporting the 
major domain sequences 
determining 
nuclear/cytoplasmic 
localization (NLS and 
NES) or important for 
binding to RNA (RRMs), 
and potential protein-
protein interactions (Gly-
rich region). The lower 
panel shows the normal 
localizations of these 
proteins in the cellular 
environment (normally 
nuclear). In normal 
conditions, TDP-43 is 
continuously shuttling 
between the nucleus and 
the cytoplasm but is 
predominant in the 
nuclear compartment. In 
the disease state, it is 
ubiquitinated, cleaved, 
phosphorylated and 
exported to the cytoplasm 
to form insoluble 
aggregates. 
The possible disease 
mechanisms (gain- or 
loss-of-function models) 
for either protein that may 
lead to neuronal loss are 
summarized in the bottom 
panels (from Buratti et. al. 
2010 [128]) 
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5.5. Scientific aims 
The underlying mechanisms of TDP-43 associated cell death are unclear. To further 
elucidate a potential gain-of-function mechanism, the major questions I wanted to 
address in my thesis are: 
• Is overexpression of wild type human TDP-43 sufficient to induce a 
neurodegeneration and a pathological phenotype similar to FTLD or ALS, 
including nuclear clearance and TDP-43-positive protein aggregates, 
hyperphosphorylation and truncation? 
• Are fALS-associated mutations in the human TDP-43 associated with a toxic 
gain-of-function? 
• Are increased level of cytoplasmic TDP-43 necessary and sufficient to induce 
neurodegenerative effects? 
In order to address these questions in vivo, we generated and analysed human 
TDP-43 transgenic animals utilizing the widely used prion protein promoter with four 
different constructs covering overexpression of wild type human TDP-43, the ALS-
related mutations M337V and G348C as well as an altered nuclear localization 
signal, inducing cytoplasmic translocation. 
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6. Materials and Methods 
6.1. Generation of human TDP-43 transgenic mice  
Human TARDBP cDNA (National Center for Biotechnologie Information 
Sequence NM_007375) was amplified by PCR from human brain cDNA and 
cloned into the pCR2.1-TOPO vector (Invitrogen). Mutations for M337V, 
G348C and a modified nuclear localization signal (NLS) [K82A;R83A;K84A] 
were inserted by site-directed mutagenesis using the QuickChange Site-
Directed Mutagenesis Kit (Agilent Technologies/Stratagene). The cDNA 
fragments TARDBP WT, M337V, G348C and NLS were subcloned in the 
“half-genomic” Prnp vector phgPrP described earlier [129]. After removal of 
most of the vector backbone, DNA fragments consisting of the promoter 
sequence and the cDNA fragments were microinjected into fertilized oocytes 
of C57BL/6JOlaHsd background. The embryos were implanted in pseudo 
pregnant mothers in collaboration with the Max Planck Institute of Molecular 
Cell Biology and Genetics in Dresden. Founders were identified by PCR 
analysis of tail DNA and bred with C57BL/6JOlaHsd mice. The newly 
generated mice were named according to the standard nomenclature for 
genetically modified mice, e.g. C57BL/6JOlaHsd-/Tg(Prnp-human TDP-WT)7, 
abbreviated WT-7. Out of 24 transgene positive founders, seven mouse 
strains with human TDP-43 overexpression were established and maintained 
in hemizygous state: human TDP-43 WT-2, WT-7, M337V-3, M337V-5, 
G348C-4, NLS-4 and NLS-6. The mice were group housed under a 12-h 
light/dark cycle with access to food and water at all times. All mouse 
experiments were performed according to Swiss federal guidelines (‘Ethical 
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Principles and Guidelines for Experiments on Animals’ 3rd edition, 2005) and 
were approved by the Animal Experimentation Committee of the Canton of 
Zurich (permit 200/2007). 
6.2.  Genotyping of human TDP-43 transgenic mice 
Weaned animals were marked by clipping small tissue pieces from the ears. 
Biopsies were lysed for genotyping according to the following protocol: 2µl 
proteinase K (Roche), 180µl distilled H2O, 20µl 10x lysis buffer [5ml 1M Tris-
HCl pH9.0, 25ml 1M KCl, 2.5ml Nonident P40, 2.5ml Tween20, 15ml distilled 
H2O]. Samples were incubated for at least 3h or overnight at 55°C with 700-
800rpm on a heat block, following heat inactivation (15min 95°C). For 
transgenic human TDP-43 the following primers were used: Forward primer: 
5'-CAACCGAGCTGAAGCATTCTGC-3'. Reverse primer: 
5'-TCCACAAAGAGACTGCGCAATC-3'. A single PCR reaction contained 9µl 
distilled H2O, 0.25µl forward primer (100 pmol/µl), 0.25µl reverse primer 
(100 pmol/µl), 12.5µl REDTaq Readymix PCR Reaction Mix (Sigma-Aldrich) 
and 3µl lysate.  The following PCR conditions were established on a 
TProfessional Thermocycler/Standard (Biometra): 95°C 5min initial 
denaturation;  95°C 30s denaturation; 57°C 30s annealing; 72°C 80s 
elongation; 35 cycles. 
PCR products were separated on a 2% agarose gel (TAE-buffer) containing 
ethidiumbromide (0.1µg/ml) by electrophoresis. Exposition to UV-light in a 
Gel DOC XR+ (Bio-Rad Laboratories) showed a single DNA band in 
transgenic mice of 801 base pairs. 
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6.3.  RIPA lysates 
Organ samples were collected, cleaned in PBS if necessary and stored 
at -20°C. Collected tissue was weighed and homogenized in ice-cold 
radioimmunoprecipitation assay (RIPA) buffer (50mM Tris–HCl, 
150mM NaCl, 5 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% sodium dodecyl sulfate) freshly supplemented with complete Protease 
Inhibitor Cocktail (Roche) and PMSF by glass homogenizer  
(5x volume/weight), followed by sonification (Bioruptor, Diagenode). The 
RIPA homogenate was centrifuged for 5min at 10,000g. The protein 
concentration of the supernatants was determined by a BCA protein assay 
(Thermo Scientific). 5x SDS–PAGE sample buffer was added to all samples 
and heated up to 95°C for 5min.  
 
6.4.  Subcellular fractionation protocol 
Cytoplasmic and nuclear fractions from brain hemispheres were prepared as 
described earlier [130]. Briefly, fresh tissue was weighed and homogenized in 
buffer containing 10mM Hepes, 10mM NaCl, 1mM KH2PO4, 5mM NaHCO3, 
5mM EDTA, 1mM CaCl2, 0.5mM MgCl2 (10× volume/weight). After 10min on 
ice, 2.5M sucrose (0.5 volume/weight) was added. 2ml of homogenate were 
centrifuged at 1,000 × g for 10min at 4°C. Supernatant was collected as 
cytoplasmic fraction. The remaining pellet was washed three times in 1.5 ml 
TSE buffer (10mM Tris, 300mM sucrose, 1mM EDTA, 0.1% Nonidet P-40), 
homogenized by sonification, and centrifuged at 4,000 × g for 5min. Finally, 
the pellet was resuspended in 200µl RIPA buffer with 2% SDS as the nuclear 
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fraction. Protease Inhibitor Cocktail (Roche) and PMSF had been added to all 
buffers prior use.  5x SDS–PAGE sample buffer was added to all and 
samples were boiled for 5min. SDS-PAGE gels were loaded with a 10 times 
more volume for cytoplasmic fraction than nuclear fraction for ratio 
adjustment. AIDA Biopackage (Raytest) was used for densiometric analyses. 
 
6.5.  SDS-PAGE and immunoblot 
A 10% SDS-PAGE was used to separate denatured proteins by their 
electrophoretic mobility according to published procedures (Table 1) [131]. 
Protein homogenates or samples from the subcellular fractionation protocol 
were mixed with a 5x SDS-PAGE sample buffer and loaded into pockets of 
stacking gel. By voltage application, negatively charged proteins were 
separated by the polyacrylamide matrix in a vertical electrophoresis unit 
(SE260, Hoefer). The fractionated proteins in the polyacrylamide gel were 
transferred to a PVDF membrane (Hybond-P, Amershan) by semi-dry-blotting 
(TE77Xp, Hoefer). Nonspecific binding sites were blocked by incubation with 
3% milk powder in Tris-buffered saline (TBS).  The membranes were probed 
overnight with primary antibodies in blocking buffer at 4°C; horseradish 
peroxidase (HRP)-labeled secondary antibodies were applied in blocking 
buffer for 1h at room temperature. Blots were developed by Lumina Forte 
Western HRP Substrate (Millipore) and digital images were acquired using a 
Stella 3200 (Raytest). AIDA Biopackage (Raytest) was used for densiometric 
analyses. 
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Table 1. Composition of 10% SDS-PAGE gels. 
Materials 10% Separation gel 
(30ml) 
Stacking gel 
(4.96ml) 
Distilled H2O 15.57ml 3ml 
1.5M Tris HCl pH8.8 7.5ml - 
0.5M Tris HCl pH6.8 - 1.25ml 
40% Polyacrylamide solution 7.5ml 0.6ml 
10% Sodium dodecyl sulfate solution (SDS) 0.3ml 0.05ml 
10% Ammonium persulfate solution  0.090ml 0.045ml 
Tetramethylethylenediamine (TEMED)  0.050ml 0.015ml 
 
6.6.  Antibodies  
6.6.1. In-house antibodies 
Monoclonal antibodies targeting pan-TDP-43 (human and murine TDP), 
murine TDP-43 and phosphorylated TDP-43 were produced by standard 
procedures in collaboration with E. Kremmer, Institute of Molecular 
Immunology, Helmholtz Center Munich [132]. The anti-pan-TDP-43 mouse 
monoclonal antibody detecting both murine and human TDP-43 was 
designated TAR5-6D6 (epitope: SMDSKSSGWGM), used 1:10 for 
immunoblots. The murine TDP-43-specific rat monoclonal antibody was 
designated TAR-M-12B4 (epitope: EDMTAEELQQFFCQYGEVVDVFI), used 
1:5 for immunoblots and 1:10 for immunofluorescence. The rat monoclonal 
antibody TAR5p-1D3 was described earlier [132] and detects phosphorylated 
serine-residues at the TDP-43 C-terminus (epitope: SMDSKpSpSGWGM) 
and was used 1:500 for immunohistochemistry. 
6.6.2. Commercial antibodies 
In addition, commercial antibodies were used. Anti-Human TDP-43-specific 
TARDBP mouse monoclonal antibody (Proteintech), was used 1:5,000 in 
immunoblots and 1:20,000 for immunohistochemistry and 
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immunofluorescence. Anti-α-tubulin rabbit polyclonal antibody (abcam), was 
used 1:5,000 in immunoblots. Anti-Histone H3-HRP rabbit polyclonal 
antibody (abcam) was used 1:500,000 for immunoblots without secondary 
antibody. Anti-CD117 clone ACK2 monoclonal rat antibody (Millipore) was 
used 1:500 for immunofluorescence. Anti-ubiquitin rabbit polyclonal antibody 
(DAKO) was used 1:1,000 for immunohistochemistry. Anti-GFAP mouse 
monoclonal antibody (NeoMarkers) was used 1:4,000 for 
immunohistochemistry. Anti-Iba-I rabbit polyclonal antibody (Wako) was used 
1:3,000 for immunohistochemistry. Secondary antibodies for immunoblotting 
were HRP-coupled goat anti-mouse, anti-rabbit (both Promega) and goat 
anti-rat IgG (Cell Signaling). For immunohistochemistry, Alexa-488, Alexa-
555 or Alexa 647-conjugated goat anti-mouse and anti-rat IgG (Invitrogen) 
were used as secondary antibodies. 
 
6.7.  RNA Extraction and TaqMan qRT-PCR 
RNA was isolated from mouse brain hemispheres (200-250mg) with the 
RNeasy Maxi Kit (Qiagen) after overnight incubation with RNA stabilization 
reagent RNAlater (Qiagen) according to manufacturer’s protocol. The 
concentration of each sample was measured by a NanoDrop 2000 
spectrophotometer (Thermo Scientific). 300ng of RNA was reverse 
transcribed using the QuantiTect Reverse Transcription Kit (Qiagen). 2ng 
cDNA was used for TaqMan qPCR amplification by a TaqMan® Gene 
Expression Master Mix specific assays (human TDP: Hs00606522_m1; 
mTDP: Mm00523866_m1; mFUS: Mn00836363_g1; GAPDH: 4352339E, Life 
Technologies). The reactions were run in single-plex assays as technical 
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duplicate, performed on a 7500 Fast Real-Time PCR System (Applied 
Biosystems), using the manufacturer's recommended standard protocol. 
Relative gene expression was calculated by the ∆∆Ct method [133]. The Ct 
(Cycle Threshold) values of both the calibrator (cDNA of non-transgenic 
animals) and the samples of interest were normalized to the relative 
abundance of the mouse GAPDH transcript. The normalized Ct values of the 
samples of interest were compared with normalized Ct of non-transgenic 
animals as calibrator. 
 
6.8.  Motor and cognitive tests 
The assessment started at 2 months of age (WT-7, twice weekly) or 10 
months of age (G348C-4 and M337V-5, every second week) for 4 months or 
10 months respectively. The motoric abilities of WT-7, G348C-4 and 
M337V-5 were assessed with three different tests. Each mouse underwent 
three trails per test with the highest score used for analysis. Prior motoric 
testing, body weight was measured. The last recorded weight was set as 0 
for statistical analysis. The different tests were performed in a consecutive 
manner with at least 10min rest period for each mouse. 
Cognitive abilities were assessed starting with 2 months of age (WT-7, or 10 
months of age (G348C-4 and M337V-5) by two different tests according to 
published procedures at the Division of Psychiatry Research, University 
Zurich [134, 135]. Only one cognitive test per day was conducted and motor 
tests and cognitive tests were performed on different days. 
All tests were carried out at the Division of Psychiatry Research, University 
Zurich. 
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6.8.1. Rotarod performance test 
Each test session started with a rotarod performance test for motor 
coordination (Ugo Basile). In this test, 5 mice were placed on a rod of 3cm 
diameter, separated by opaque plastic walls. The rod accelerated linearly 
from 4 to 40rpm within 180s. Mice dropping off the rod activated a switch 
recording time point and current acceleration. 
6.8.2.  Paw Grip Endurance (PAGE) 
A Paw Grip Endurance (PAGE) was performed by placing mice upside-down 
on a wire grid, holding tight with all four limbs. The time was recorded until 
the mouse lost its grip. Otherwise, the test was stopped after 120s.  
6.8.3. Grip strength 
Grip strength of maximal muscle strength of combined forelimbs and hind 
limbs was assessed by a grip strength meter (Ugo Basile). The mice were 
allowed to peg to a wire grid which is connected to a force sensor. By pulling 
the mice backwards at the tail, they instinctively applied a counteracting 
force. The grip strength meter recorded the highest applied force in grams.  
The assessment started at 2 months of age (WT-7, twice weekly) or 10 
months of age (G348C-4 and M337V-5, every second week) for 4 months or 
10 months respectively. 
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6.8.4. Novel Object Recognition Test (NORT) 
Single mice were placed in the centre of a brightly-lit white Plexiglas box 
(50x50cm2), and their movements (distance travelled, maximum speed, 
immobile time and time spend in centre) were tracked using ANY-maze video 
tracking software (Stoelting) for 15min during habituation period. Center area 
was defined as the area 5cm away from the walls. After habituation period, 
the mice were removed from the box for 2min. The box included two circles of 
10cm diameter in diagonally opposite corners named object zones. Two 
simple objects of the same color and shape were placed in the object zones. 
The mice were placed in the centre of the box for a 5min familiarization 
period. Object interaction was assumed when the head of a mouse entered an 
object zone. After familiarization period, the mice were removed from the box 
for 2min. A differently colored and shaped object of the same size replaced 
one of the two objects. The mice got 5min time for interaction with the now 
different objects, one familiar and one unfamiliar. The ratio between novel 
object and familiar object was divided by the same object ratio gained in the 
familiarization period to calculate the novel zone preference unaffected by 
general object preference. 
6.8.5. Y-Maze 
Spatial working memory was assessed in mice using the Y-Maze (Y-shaped 
plastic maze, with 40 × 20 × 10cm3 arm sizes). During a 5min trial, the 
sequence of arm entries as well a maximum speed, immobility time and 
traveled distance were recorded using the ANY-maze Video Tracking System 
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(Stoelting). The percentage alternation was calculated as the ratio of actual to 
possible alternations (defined as the total number of arm entries2) × 100%. 
 
6.9.  Histology, immunohistochemistry and double-label immunofluorescences 
Collected tissue was immediately placed in 10% formalin solution and fixed for 
at least for 24h. Immunohistochemistry (IHC) was performed on 5-µm thick 
sections of formalin-fixed paraffin-embedded tissue on glass slides. The 
procedure for DAB staining followed the protocol provided with the NovoLink 
Polymer Detection Kit (Leica): Sections were de-paraffinized in xylene and re-
hydrated through graded alcohols finalized by distilled water. For antigen 
retrieval, the sections were boiled for 5x 3min in citrate buffer pH6.0 using a 
microwave oven, followed by a wash step with distilled water and 10-15min of 
hydrogen peroxide treatment with 3% (v/v) solution in distilled water and 
consecutive wash steps with PBS. Sections were blocked for 30min with 1% 
BSA, 0.5% Triton-X in PBS. Primary antibodies were applied for 24h at 4°C in 
0.5% BSA, 0.25% Triton-X in PBS. After consecutive wash steps with PBS, 
the sections were incubated with Post Primary solution (included in the kit) for 
30min. After consecutive wash steps with PBS, the sections were incubated 
with Novolink Polymer (included in the kit) for 30min, followed by consecutive 
wash steps with PBS. The polymer is linked with peroxidase. DAB working 
solution was applied on the sections, resulting in a brownish precipitate by 
oxidation of DAB. The reaction was stopped with PBS after 1 to 5min of 
incubation. Finally, the sections were dehydrated in graded alcohols and 
mounted with a cover slip using HICO-MIC embedding medium (Hirtz). IHC 
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images were obtained with a DM100 LED light microscope, equipped with a 
DFC295 camera (both Leica). 
Double-label immunofluorescence (IF) on paraffin embedded tissue samples 
was performed according to a similar protocol without hydrogen peroxide 
treatment. Sections were incubated with secondary fluorescence antibodies 
for 2h. Hoechst 33342 (1:5000) was used for nuclear counterstaining and 
Fluorescence Mounting Medium (Dako) for final mounting. IF images were 
obtained with a DM5000B fluorescence microscope system, equipped with a 
DFC345FX camera (both Leica). 
 
6.10. Morphometric analysis of intestine  
Intestines were fixated in 10% formalin solution. Six transverse, consecutive 
sections of 5mm were taken from the proximal part of the duodenum, the 
terminal ileum and the proximal colon, paraffin-embedded, cut and stained 
with H&E. Slides were scanned with a Nanozoomer C9600virtual slide light 
microscope scanner (Hamamatsu). The circumference of each section as 
well as the muscle thickness of the longitudinal and circular muscle were 
assessed on digital slides. The diameter of each sample was calculated from 
the circumference, whereas the muscle thickness was measured at three 
triangular points using the NDP.view program (Hamamatsu).  
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6.11. Whole mount preparation of myenteric plexus, Azure II-staining and 
ganglion cell counting 
Fresh terminal ileum and proximal colon, each 3cm long, were opened along 
the mesenteric border, cleaned in cooled PBS and mounted with needles on 
a polystyrene block. Three animals had been used per genotype. Fixation 
was done for 45min in 10% formalin solution. Samples were rinsed with PBS 
and mucosal layer was removed under a stereomicroscope. Cleaned muscle 
layers containing the myenteric plexus were air-dried on glass slides with the 
circular muscle facing up for 30min. Azure II (Sigma-Aldrich) was prepared as 
0.2% solution in distilled water and filtered by a syringe-mounted 0.40µm 
filter. Slides were placed on preheated hot plate (70°C) and immediately 
incubated with the Azure II solution for 20s and stopped by a wash step with 
PBS. Wash steps were performed with 70% ethanol and PBS, ending with a 
final dehydration in 100% ethanol and mounting with a glass coverslip. 
Azure II-stained cells were manually counted using a bright field light 
microscope DM100 LED (Leica) at 100x magnification representing 3.547 
mm2 as following: four consecutive fields of view were selected starting at the 
proximal end of the specimen with the anti-mesenteric border as midline. To 
correct for the intestinal dilatation in the WT-7 lines, numbers were divided by 
the circumference ratio compared to non-transgenic controls. 
 
6.12. “Swissrole technique” for histological analysis of acetylcholine esterase 
activity and c-Kit immunoreactivity 
Longitudinal specimen of the intestine were prepared as described earlier 
[136]. Briefly, freshly dissected small intestine and colon were cleaned in 
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PBS and opened along the mesenteric border. The tissue was cut into 10cm 
parts, rolled up with the mucosa facing out and quick-frozen for cryo-
sectioning. 
Acetylcholine esterase activity was determined as described before [137]. 
Thawed specimen were fixated with 10% formalin solution with 1% (w/v) 
calcium chloride for 30s and washed with tap water. The specimens were 
incubated with a 1:1 mix of two solutions, adjusted to pH6.0: solution A 
(0.1M sodium acetate, 0,1M sodium citrate, 30mM cupric sulfate solution, 
4mM iso-OMPA (tetraisopropylpyrophosphoramide), 0.005% 
(w/v) acetylcholine iodide, diluted in ddH20) and solution B (0.165% (w/v) 
potassium ferricyanide in ddH20) for 1h on 37°C. 
After washing with ddH20 and incubation with 1% (w/v) ammonium sulfate 
solution, the specimens were washed with tap water and ddH20, followed by 
1min incubation with 0.1% (w/v) silver nitrate solution and another wash step 
with ddH20. The specimens were fixed with 10% formalin solution for 5s, 
washed with tap water and ddH20 and finally counterstained by 1min 
incubation with haematoxylin solution and washed with ddH20 and tap water. 
The product of the cholinesterase activity, thiocholine, reduces ferricyanide to 
ferrocyanide, which precipitates as copper ferrocyanide directly at the site of 
enzymatic activity. Images were obtained with a DM100 LED light 
microscope, equipped with a DFC295 camera (both Leica). 
c-Kit immunofluorescence on cryo-sections was done as following: The 
“Swissrole technique” intestinal specimens were thawed for 25min, following 
5min fixation with cooled aceton and 10min of air dry. They were treated with 
0.1M Tris‐HCL pH7.5 for 5min and incubated with anti-c‐KIT antibody in 0.1M 
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Tris‐HCL pH7.5 + 2% FBS for 1h. A wash step with 0.1M Tris‐HCL pH7.5 for 
5min was repeated 3 times, followed by 1h incubation with the secondary 
antibody in 0.1M Tris‐HCL pH7.5 +2% FBS. Nuclear counterstaining was 
achieved by 10min incubation with Hoechst 33342 diluted 1:5000 in 0.1M 
Tris‐HCL pH7.5. IF images were obtained with a DM5000B fluorescence 
microscope system, equipped with a DFC345FX camera (both Leica) 
 
6.13. Surgery and 17β-estradiol treatment of WT-7 animals 
WT-7 male and female mice (n=11/12) were castrated at 28 to 37 days of 
age and compared to sham operated human TDP-43 WT-7 mice (n=12/12). 
Anesthesia and surgery was performed according to established methods 
(2-5% Sevoflurane, pain treatment with Carprofen twice daily for 3 days) 
followed by daily monitoring for general movement, body shape and clinical 
symptoms. End stage animals are defined by 7% weight loss over 7 days, a 
hunchback and a reduced motility (2 of 3 criteria need to match) (Table 2). 
Furthermore, female human TDP-43 WT7 mice were ovariectomized and 
administered 17β-estradiol using 90-days’ time release pellets with two 
different concentrations (high dose: 0.002mg/day (n=12); low dose: 
0.004mg/day (n=6); Innovative Research of America, USA). As controls 
WT-7 females (n=12) animals underwent placebo treatment. The successful 
abolishment of gonadal steroids by ovariectomy and the reconstitution via of 
17β-estradiol administration was controlled by measuring the uterus wet 
weight. 
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Table 2. Control criteria for transgenic WT-7 animals to define clinical endpoint 
 Symptoms Result/Action Score (total ≥2 = 
endpoint) 
Spontaneous and 
provoked movement 
(tactile stimulation)? 
Reduced motility? = 1 
No motility? = 2 
0, 1 or 2 
Roundish body shape; 
expanded belly? 
If yes: 1 0 or 1 
Unexpected clinical 
symptoms, indicating pain, 
burden or disease? 
Veterinary clarification; 
control twice daily as long as 
the problem persist 
0 or 2 
Body weight Loss of body weight within a 
week by >7%? 
= 2 
0 or 2 
 
6.14. Statistical analysis 
The statistical analysis were performed with Graphpad Prism, Version 6.01, using 
statistical methods described here [138]. 
One-way-ANOVA was used to compare three or more unmatched groups. The 
Dunnett´s-test was used was used as a multiple comparison post-test to compare 
the mean of each column to the mean of a control column. Tukey’s test was used for 
multiple comparisons when comparing each group with each other group. 
An unpaired Student´s t-test (two-sided) was used to compare two groups. For 
longitudinal studies, two-way-ANOVA with Sidak’s multiple comparison post-test was 
used.  
The nonparametric Log-rank (Mantel-Cox) test was used to compare the survival 
distributions of survival curves. 
Significance levels were set at p<0.05 for all analyses. Data are presented as means 
± standard deviation (SD) if not marked differently. 
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The statistical test, p-values and the n for each statistical analysis are indicated in 
each of the corresponding figure legends. 
7. Results 
7.1. Generation of human TDP-43 transgenic mouse lines 
At first, transgenic mice with a comparable expression level and expression pattern 
of human TDP-43 had to be generated. Four different transgenic constructs were 
created by integrating the cDNA sequence of human wild type TDP-43 (WT), human 
TDP-43 bearing ALS-associated mutations (M337V, G348C) or human TDP-43 with 
a disrupted NLS-sequence (NLS) in the phgPrP Vector. M337V and G348C are two 
TDP-43 mutations associated with fALS and TDP-43 proteinopathies (Figure 4) [15, 
34, 38, 39, 139-142]. We utilized the prion protein (Prnp) promoter known for a 
strong and persistent expression in neurons and a subset of glial cells of the central 
and peripheral nervous systems, accompanied by an expression in non-neuronal 
tissue such as liver, spleen and intestine [129, 143]. The Prnp-promoter human 
TDP-43 constructs were linearized and microinjected into C57BL/6JOlaHsd oocytes 
and implanted into pseudopregnant females at the Transgenic Core Facility, Max 
Planck Institute of Molecular Cell Biology and Genetics, Dresden. 
 
Figure 4. Functional elements of the human TDP-43 protein and inserted mutations. 
Schematic diagram of the TDP-43 protein domain structure showing the mutated sites in the 
human TDP-43 of generated TDP-43 transgenic animals. M337V and G348C are human 
pathogenic ALS-associated mutations whereas NLS refers to a disrupted nuclear localization 
signal (NLS). The nuclear export signal (NES) remained unchanged in all transgenic lines.  
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PCR analysis of genomic DNA from offsprings for positive integration of the 
transgenes revealed eleven founders for the human TDP-43 WT, five founders for 
human TDP-43 M337V, eight founders for human TDP-43 G348C and eight 
founders for human TDP-43 NLS constructs (Table 3). Germline transmission of the 
transgene was confirmed for 15 founder mice by breeding the founder mice with 
C57BL/6JOlaHsd mice. 
Offspring from each founder were investigated by immunohistochemistry and 
immunoblot analysis using a human TDP-43 specific antibody to select for those with 
comparable transgene expression levels and expression patterns for the four 
different TDP-43 constructs. One WT line (WT-7), two M337V lines (M337V-3, 
M337V-5), one G348C line (G348C-4) and two NLS lines (NLS-4, NLS-6) were 
successfully established, characterized by germline transmissibility and ubiquitous 
pan-neuronal human TDP-43 protein expression in the central nervous system 
(CNS) with comparable expression levels (Figure 5). G348C-6 shared the same 
features, but could not be established as strain because of breeding difficulties. 
Since Prnp-driven expression of a transgene has been reported in different tissues 
besides the CNS we also investigated for transgene expression in other organs 
(Figure 5 A). All lines showed a similar expression pattern of human TDP-43 
transgene at the age of 2- to 3-month with a high expression in the central nervous 
system represented by brain and spinal cord as well as high but more variable 
TDP-43 levels in the cecum and colon, speaking for a strong expression in the 
enteric nervous system. Expression in other organs or tissues was not detectable. 
Other lines with germline transmission only revealed a mosaic expression pattern in 
a subset of neurons in the brain or no transgene expression and were therefore not 
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further established. WT-2 showed only weak expression in the CNS and strong 
expression in the skeletal muscles not seen in the other mouse lines and was 
therefore not included in the future studies. 
Table 3. Human TDP-43 transgenic founder mice with the seven established 
transgenic mouse lines highlighted in grey. 
Founder name (short form) Germline transmissible human TDP-43 protein in 
the CNS 
WT-1 (1st injection) yes no 
WT-2 (1st  injection) no  
WT-3 (1st injection) no  
WT-4 (1st  injection) no  
WT-2 (2nd injection) yes yes, but very weak 
WT-3 (2nd injection) no offspring  
WT-4 (2nd injection) no  
WT-5 (2nd injection) founder died  
WT-6 (2nd injection) no  
WT-7 (2nd injection) yes yes 
WT-8 (2nd injection) yes no 
NLS-1 no  
NLS-2 no  
NLS-3 yes yes, but weak and focally 
NLS-4 yes yes 
NLS-5 no  
NLS-6 yes yes 
NLS-7 no  
NLS-8 no  
G348C-1 no  
G348C-2 yes no 
G348C-3 yes no 
G348C-4 yes yes 
G348C-5 no offspring  
G348C-6 yes, but bad breeding yes 
G348C-7 founder died  
G348C-8 yes yes, but weak and focal 
M337V-1 no offspring  
M337V-2 no offspring  
M337V-3 yes yes 
M337V-4 yes yes, but only single cells 
M337V-5 yes yes 
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Figure 5. Expression of human 
TDP-43 in different organs of 
human TDP-43 transgenic mice. 
 
(A) Immunoblot analysis with a 
human TDP-43 specific antibody in 
different organs of 2- to 3-month-
old transgenic males. All lines 
show a similar expression pattern 
with high human TDP-43 levels in 
brain and spinal cord and a more 
variable expression in the cecum 
and colon. 50 µg of RIPA lysate 
were loaded. 
 
(B) Immunohistochemistry with a 
human TDP-43 specific antibody 
illustrates the panneuronal Prnp-
promoter driven expression of 
human TDP-43 expression in brain 
and spinal cord of 6-month-old 
females. In cortical neurons, 
human wild type TDP-43 and 
TDP-43 with M337V and G348C 
mutation is largely localized to 
neuronal nuclei. The two NLS-
mutant lines both show a strong 
shift to the cytoplasm in addition to 
a nuclear expression. In motor 
neurons in the anterior horn of the 
spinal cord, all lines show a strong 
nuclear and weak cytoplasmic 
immunoreactivity. Scale bar: 20µm 
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7.2. Subcellular localization of transgenic and endogenous TDP-43 
We performed immunohistochemistry staining on brain and spinal cord material with 
a human specific TDP-43 antibody to assure pan-neuronal transgene expression in 
all established lines and to examine the subcellular distribution of TDP-43. Both 
genders have been included in a longitudinal analysis ranging from 1 to 24 months. 
We did not observe an influence of gender or age on the expression pattern or 
localization of human TDP-43. Selected images represent adult 6-month-old females 
( 
Figure 5 B). 
In the transgenic mouse lines WT-7, M337V-3, M337V-5 and G348C-4, human 
TDP-43 is predominantly localized to the nucleus in most of neuronal cells, 
resembling the localization of endogenous TDP-43 in humans and mice. The motor 
neurons in the anterior horn showed an increased cytoplasmic immunoreactivity 
compared to other transgene-expressing cells. However, it is probably not a 
pathogenic redistribution as TDP-43 accumulation in the cytoplasm of motor neurons 
has been observed in aging non-transgenic mice [144]. 
Disruption of the human TDP-43 NLS-sequence in the NLS-4 and NLS-6 mouse 
lines resulted in a strong cytoplasmic immunoreactivity for human TDP-43 in all 
transgene-expressing neurons in addition to nuclear localization. Notably, nuclear 
localization of TDP-43 was not fully abolished by the three amino acid substitution in 
the NLS in vivo in contrast to results observed in cultured cells [109], but in line with 
studies in other rodent models [111, 112]. This might be explained by dimerization of 
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TDP-43 with NLS mutation and wild type TDP-43 and subsequent nuclear uptake 
[76]. 
The human TDP-43 both in the nucleus and in the cytoplasm was diffusely 
distributed without indication of a pathological nuclear clearance of TDP-43 or the 
formation of TDP-43 aggregates. 
At next, we wanted to confirm and quantify the subcellular distribution pattern of 
TDP-43 biochemically by subcellular fractionation and immunoblots using brain 
homogenates. In particular, we were also interested to analyse the distribution of 
endogenous murine TDP-43 to see weather transgenic TDP-43 expression might 
influence endogenous TDP-43. This required an antibody targeting specifically the 
endogenous murine TDP-43.  Since no commercial murine TDP-43 specific antibody 
was available we generated own monoclonal antibodies. The human and mouse 
TDP-43 protein share a sequence identity of 96.1%, making the generation of a 
discriminating antibody challenging. In collaboration with Elisabeth Kremmer, 
Institute of Molecular Immunology, Helmholtz Center Munich, rats were immunized 
with a peptide corresponding to amino acids 201 to 223 of the murine TDP-43 
protein sequence. This region has a lower similarity between human and murine 
amino acid composition with only 69.6% sequence identity with 7 different amino 
acids. 180 hybridoma subclones were tested for the production of a monoclonal 
murine specific TDP-43 antibody by immunoblot. One clone (TAR-M-12B4) was 
identified being able to discriminate between murine and human TDP-43 with a 
detection of a band at 43kDa in mouse brain tissue but not in human HEK293T cells. 
( 
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Figure 6). This result was confirmed by IHC staining using paraffin-embedded 
mouse and human brain tissue (not shown). 
 
 
 
 
Figure 6. TAR-M-12B4 recognizes murine TDP-43 but not 
human TDP-43. Immunoblot probed with the TAR M-12B4 
antibody comparing non-transgenic mouse brain 
homogenate and human embryonic kidney (HEK-293) cell 
lysate. Murine TDP-43 appears in the mouse brain 
homogenate at 43kDa while human TDP-43 is not detected. 
80µg of RIPA lysates were loaded.  
 
We performed a subcellular fractionation protocol using total brain homogenates of 
2-month-old males of each mouse line to separate nuclear and cytoplasmic TDP-43 
and performed immunoblots analysis using the antibodies TAR5-6D6,  Anti-Human 
TDP-43-specific TARDBP mouse monoclonal antibody (Proteintech) and 
TAR-M-12B4 to detect total, human and mouse TDP-43, respectively (Figure 7 A). 
The correct subcellular fractionation was verified with antibodies against histone H3 
as marker for the nuclear fraction and tubulin as marker for the cytoplasmic fraction. 
The cytoplasmic/nuclear ratios of human TDP-43, endogenous murine TDP-43 and 
total TDP-43 were comparable in the mouse lines WT-7, M337V-3, M337V-5, 
G348C-4, revealing a much lower TDP-43 concentration in the cytoplasm compared 
to the nucleus (Figure 7). Neither did the ALS-associated mutations negatively 
influence nuclear uptake of human TDP-43 nor did the general overexpression of 
TDP-43 change the subcellular localization of endogenous TDP-43. Accordingly, 
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pan-TDP-43 and endogenous TDP-43 ratios of WT-7, M337V-3, M337V-5 and 
G348C-4 were not changed compared to non-transgenic controls. 
Altering the NLS resulted in a significant increase (~8 fold, p<0.05) of the 
cytoplasmic/nuclear ratio of human TDP-43, compared to the mouse lines WT-7, 
M337V-3, M337V-5 and G348C-4 (Figure 7 C), in line with an inhibited nuclear 
uptake of human TDP-43 bearing a mutated NLS-sequence. Consequently, the pan-
TDP-43 cytoplasmic/nuclear ratio increased significantly (~2.5 fold, p<0.0001 
Figure 7 B), while the cytoplasmic/nuclear ratio of murine TDP-43 remained 
unaffected compared to non-transgenic controls (Figure 7 D), speaking against a 
retention effect of NLS-mutated human TDP-43, i.e. increased cytoplasmicTDP-43 
did not entrap endogenous TDP-43 or a disturb of the nuclear uptake mechanism 
due to overexpression of a protein with an altered NLS. 
By the previous experiments, we could exclude an influence of human TDP-43 
expression on the subcellular localization of endogenous murine TDP-43. 
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Figure 7. NLS mutation 
leads to a cytoplasmic 
shift of human TDP-43. 
Immunoblots using ratio-
adjusted subcellular 
fractionations of total brain 
homogenate of 2-month-old 
males probed with 
antibodies detecting total 
TDP-43, human TDP-43 
murine TDP-43, 
respectively. (B) A 
densiometric analysis of 
band intensities showed a 
comparable total TDP-43 
cytoplasmic/nuclear ratio of 
~0.08 in non-transgenic, 
WT-7, M337V-3, M337V-5 
and G348C-4, while 
significant decrease up to 
~0.2 is seen for NLS-4 and 
NLS-6. (C) Both NLS mutant 
lines show a ~8-fold higher 
level of human TDP-43 in 
the cytoplasm compared to 
WT-7, M337V-3, M337V-5 
and G348C-4. (D) Similar 
cytoplasmic/nuclear rations 
are observed for all 
transgenic lines and non-
transgenic controls 
demonstrating that the 
redistribution of human 
TDP-43 in the NLS-lines 
does not affect the 
cytoplasmic/nuclear ratio of 
murine TDP-43. Tubulin is 
used as cytoplasmic marker; 
histone H3 as nuclear 
marker. Data are based on 
triplicates and shown as 
means ± SD; One-way-
ANOVA with Dunnett`s 
multiple comparisons; 
*p<0.05, ****p<0.0001 
compared to non-transgenic 
controls (total TDP-43; 
murine TDP-43) and WT-7 
(human TDP-43) 
respectively. 
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7.3. Downregulation of endogenous TDP-43 upon transgenic TDP-43 
expression is independent of TARDBP mutations and subcellular 
localization 
It was demonstrated in vitro that the TDP-43 protein is able to bind specific regions in 
its own 3’UTR, activating a normally silent intron 7 in the 3′-UTR, leading to an 
altered subcellular distribution of the TARDBP mRNA that is mostly retained in the 
nucleus and degraded [145, 146]. The TDP-43 protein levels are thereby tightly 
regulated by an autoregulatory feedback mechanism. We therefore investigated a 
possible regulatory effect of transgenic human TDP-43 on the expression levels of 
endogenous TDP-43 in vivo. 
First, we compared the mRNA expression levels by quantitative reverse 
transcriptase-PCR (qRT-PCR) using RNA extracted from brains of 3-month-old 
males. We utilized human and murine TARDBP-specific TaqMan probe sets, based 
on the detection of fluorogenic labels during PCR amplification. GAPDH was used 
for normalization. The highest human TDP-43 mRNA expression was observed in 
the WT-7 line, compared to ~50% in the other transgenic lines (Figure 8 A). 
Non-transgenic animals were negative for human TDP-43 (not shown). In line with 
the described autoregulation of TDP-43 expression in vitro, we observed a significant 
decrease of the endogenous murine TDP-43 transcript by 40% (p<0.05 / p<0.01) 
with the exception of the M337V-3 and NLS-6 with ~10% and ~30% (p>0.05), 
respectively, in the brains expressing the human transgene compared to 
non-transgenic controls, independent of human TDP-43 localization or ALS-
associated mutations (Figure 8 B). 
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Figure 8. Human TDP-43 overexpression down regulates endogenous murine TDP-43 
but does not alter FUS expression. qRT-PCR using mRNA isolated from whole brain 
tissue. (A) The WT-7 line shows the highest mRNA levels for transgenic human TDP-43 (B) 
Expression of human TDP-43 results in a decrease of murine TDP-43 mRNA in WT-7, 
M337V-5, G348C-4, NLS-4 and NLS-6. (C) Expression of different human TDP-43 proteins 
does not influence the expression levels of FUS/TLS transcript. GAPDH used for 
normalization; 3 males per genotype, 3-month-old; Data are means ± SD; One-way-ANOVA 
with Dunnett´s test multiple comparisons *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
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The ALS-associated protein FUS/TLS (Fused in Sarcoma / Translocated in 
Liposarcoma) has a high structural similarity to TDP-43, both implicated in a wide 
range of cellular activities, including transcription, alternative splicing, mRNA 
stability, and RNA-protein granule formation [147]. The 3′UTR of FUS mRNA and 
introns 6 and 7 contain TDP-43 binding sites [55].  TDP-43 binding potentially alters 
transcript stability and translation rate. We therefor quantified the FUS mRNA levels 
in the same samples used for TARDBP mRNA comparisons to investigate potential 
alterations of FUS expression; however, no differences in FUS mRNA expression 
were detectable in our human TDP-43 transgenic mice (Figure 8 C). 
To investigate the autoregulatory effects of TDP-43 on protein level, brain 
homogenates of 3- to 5-month-old human TDP-43 transgenic males and 
non-transgenic controls were used to quantify total, human and murine TDP-43 
levels in the different transgenic mouse lines by immunoblots. The newly generated 
antibody TAR-M-12B4 was used to detect the murine TDP-43. For densitometric 
analysis bad intensities of TDP-43 were normalized to tubulin (Figure 9 A).  
WT-7 and G348C-4 showed the highest expression levels of human TDP-43 protein 
with G38C-4 reaching 80% of the WT-7 level (p>0.05). M337V-3, M337V-5, NLS-4 
and NLS-6 expressed ~25% of the WT-7 human TDP-43 level respectively 
(p<0.0001) (Figure 9 B). No human TDP-43 was detected in non-transgenic 
animals. However, the protein levels of total TDP-43 remained comparable between 
the transgenic lines and non-transgenic males of the same age suggesting that 
transgenic TDP-43 expression lowers the murine TDP-43 protein levels. This was 
confirmed by immunoblots with the murine TDP-43 specific antibody showing a 
reduction of murine TDP-43 in all transgenic lines compared to non-transgenic mice. 
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The reduction of endogenous TDP-43 was strongest in the WT-7 line (~77%, 
p<0.0001), followed by M337V-3, G348C-4 and NLS-6 (~40%, p<0.05 / p<0.01%). 
Therefore WT-7 showed the highest expression of human TDP-43  and the strongest 
downregulation of endogenous murine TDP-43. 
 
Figure 9. TDP-43 protein levels in the brain of human TDP-43 transgenic mice. (A) 
Brain homogenates of 2- to 5-month-old males expressing human TDP-43 under the control 
of the PrnP-promoter probed with antibodies detecting total TDP-43, human TDP-43 or 
murine TDP-43 respectively. 35µg of RIPA extract are loaded. (B) A densitometric analysis 
of immunoblots using 3 individuals per genotype shows that the WT-7 line has the highest 
expression of human TDP-43, followed by G348C-4 with ~80% and M337V-3, M337V-5, 
NLS-4 and NLS-6 with ~25% compared to WT-7. All transgenic lines have comparable 
levels of total TDP-43 levels between 69 and 128% compared to non-transgenic controls. 
WT-7 shows the strongest reduction of endogenous murine TDP-43 of ~77% speaking for a 
correlation with the human TDP-43 expression. Data are means ± SD; One-way-ANOVA 
with Dunnett´s test multiple comparisons *p<0.05, **p<0.01, ****p<0.0001 
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The expression level dependent autoregulation of murine TDP-43 was confirmed on 
a cellular level by double label immunofluorescence staining with mouse and human 
TDP-43 specific antibodies in brain tissue of the M337V-5 founder with a mosaic 
expression pattern (Figure 10). The expression of high levels of human TDP-43 
resulted in a strong reduction of murine TDP-43. 
 
Figure 10. Autoregulatory effect of human TDP-43 on the murine TDP-43 expression.  
Comparison of human and murine TDP-43 expression in the hippocampal neuron nuclei of 
the human TDP-43 M337V-5 founder animal with mosaic expression pattern by double label 
immunofluorescence. In the absence of transgenic human TDP-43, endogenous TDP-43 
levels are higher compared to cells expressing transgenic human TDP-43. 
In summary, the results demonstrate an autoregulatory effect of transgenic human 
TDP-43 protein expression on the endogenous murine TARDBP transcript and 
protein levels in vivo thereby confirming previous in vitro studies. Notably, the 
downregulation of endogenous TDP-43 is dependent on the protein levels of 
transgenic TDP-43 but not obviously affected by human pathogenic TARDBP 
mutations and the subcellular distribution of transgenic TDP-43. 
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7.4. Overexpression of human wild type TDP-43 leads to premature death in 
WT-7 
To investigate functional consequences of human TDP-43 expression, we performed 
longitudinal studies by a frequent monitoring program, including the ability and 
willingness to move, the body shape and body weight control. Furthermore, we 
conducted motoric and cognitive tests at different time points. We observed a 
premature death in the WT-7 line compared to non-transgenic controls with a mean 
lifespan of 133.6±39.7 days (p<0.0001). The life expectancy of the other human 
TDP-43 transgenic lines remained unchanged compared to non-transgenic controls 
(Figure 11 A). End stage WT-7 animals revealed a swollen abdomen, a hunchback 
appearance and a reduced activity compared to non-transgenic littermates 
(Figure 11 B). By breaking down the survival data of WT-7 animals according to the 
gender, we observed a significant gender-dependent difference in survival times 
(mean lifespan: 103±16.7 days in males compared to 157.5±33.4 days in females, 
p<0.0001) (Figure 11 C). Both genders of WT-7 showed a tendency towards a lower 
body weight during the presymptomatic phase and a significant loss of body weight 
during the weeks before death (Figure 11 D). The altered body shape and reduced 
activity were observed in both genders. Based on these findings, we modified the 
health monitoring of the WT-7 line with defining termination criteria based on the 
body shape, activity and body weight loss within one week (Table 2). Given that 
WT-7 develops its characteristic phenotype quite rapidly, we monitored the animals 
on a daily basis starting with the age of 60 days for males or 95 days for females. 
Animals reaching the defined endpoint criteria were euthanized. 
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None of the other human TDP-43 transgenic lines showed a pathological phenotype 
or an altered lifespan similar to WT-7. Both genders were indistinguishable from 
non-transgenic littermates. 
 
Figure 11. WT-7 animals die premature compared to the other human TDP-43 
transgenic animals with an earlier onset in males and weight loss prior death (A) WT-7 
animals die premature with an mean lifespan of 133.6±39.7 days in contrast to the other 
transgenic lines showing a normal life expectancy compared to non-transgenic littermates 
(WT-7 n= 47; nontg n=25; G348C-4 n=21; M337V-3 n=11; M337V-5 n=20; NLS-4 n=15; 
NLS-6 n=24; including both males and females). (B) End stage female mouse, 69 days old, 
showing a hunchback appearance with a swollen abdomen, reduced motoric activity and 
rapid weight loss over 2 to 3 days. The end stage phenotype is identical in males and 
females. (C) WT‐7 males show a significantly reduced life span compared to transgenic 
females (mean lifespan: 103±16.7 days compared to 157.5±33.4 days, n=23/24). (D) A 
reduced body weight is observed in WT-7 animals of both genders compared to 
non-transgenic littermates with a significant drop close to death. Survival data are analysed 
by Log-rank (Mantel-cox) test; body weight by Two-way-ANOVA with Sidak multiple 
comparisons. Bars represent means ± SD; *p<0.05, **p<0.01, ****p<0.0001 
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7.5. Phenotype in WT-7 is due to alterations of the gut 
End stage WT-7 animals showed a swollen abdomen. Closer examination at autopsy 
revealed a consistent dilatation of the lower ileum, cecum and upper colon in both 
genders, all filled with intestinal contents (Figure 12 A). To quantify these 
alterations, the circumference and thickness of the muscular layers were measured 
on six consecutive sections of the proximal duodenum, distal ileum and proximal 
colon of formalin-fixated, paraffin-embedded tissue from end stage WT-7 males and 
non-transgenic littermates. 
We observed a strong dilatation of the ileum and a less pronounced dilatation of the 
duodenum and colon of WT-7 males shown by an increase in diameter compared to 
non-transgenic littermates (duodenum: 2597.88±364.44 µm vs. 2314.26±226.10 µm, 
p<0.01; ileum: 4273.73±406.19 µm vs. 2255±281.83 µm, p<0.0001; colon: 
3909.60±1107.77 µm vs. 2813.34±615.09 µm, p<0.01) (Figure 12 B). A muscular 
hypertrophy was seen in the circular and longitudinal muscle layers of the ileum 
(circular muscle: 43.66±13.94 µm vs. 26.58±9.35µm, p<0.0001; longitudinal muscle: 
28.52±10.02µm vs. 18.05±8.24µm, p<0.05) as well as in the longitudinal muscle of 
the colon (22.36±10.91µm vs. 17.27±9.06µm, p<0.01) (Figure 12 C), while both 
muscle layers in the duodenum and the circular muscle layer in the colon revealed 
no changes in muscle thickness (duodenum circular muscle: 18.07±6.11µm vs. 
20.02±7.30µm, p=0.1351; duodenum longitudinal muscle: 12.96±4.60µm vs. 
13.93±5.28µm, p=0.3075; colon circular muscle: 73.88±35.05µm vs. 
67.34±25.21µm, p=0.2680) 
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Figure 12. End stage WT-7 animals have an increased intestinal diameter in the 
duodenum, ileum and colon and thickened muscular layers in the ileum and colon. (A) 
End stage WT-7 animals of both genders have a dilated ileum, cecum and colon. (B) End 
stage WT-7 males show an increased diameter of the duodenum, the distal ileum and the 
proximal colon, more pronounced in the ileum (C) Muscle hypertrophy was observed in the 
circular and longitudinal muscle layer of the ileum as well as in the longitudinal muscle layer 
of the colon. Data are analysed by unpaired t-test; bars represent means ± SD; **p<0.01, 
****p<0.0001 
The data argue for alterations of the gut motility in WT-7. As demonstrated by 
immunoblots in Figure 5, all transgenic lines showed human TDP-43 expression in 
the gastrointestinal system. To further examine the cell types expressing human 
TDP-43, we performed IHC-staining on the ileum and colon of 6-month-old females, 
including end stage WT-7 females. All our transgenic lines showed an expression of 
human TDP-43 mainly restricted to ganglia cells in the myenteric plexus 
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(Figure 13 A), localized between the circular and longitudinal muscular layer in the 
gastrointestinal tract. The myenteric plexus forms a crucial part of the enteric 
nervous system (ENS) as it innervates both muscle layers and controls the 
gastrointestinal tract motility autonomously. We concluded that the phenotype of the 
WT-7 mice is most likely due to dysfunction of the ENS. Importantly, the presence of 
transgenic TDP-43 expression in the ENS in all transgenic mouse lines excludes that 
the phenotype in the WT-7 is due to a unique expression pattern in this line and 
argues for a specific dysfunction of the ENS upon human wild type TDP-43 
expression.  
To investigate whether the phenotype is associated with a reduction of neurons, we 
quantified the number of neurons in the myenteric plexus in 3 months old end stage 
WT-7 animals compared to non-transgenic littermates and age-matched males of the 
mouse lines M337V-5 and G348C-4. Distal ileum and proximal colon samples were 
gathered from three animals per group. The fixed muscular layers including the 
myenteric plexus were separated from the mucosa layers and stained as partial 
whole-mount with Azur II for investigation of neurons. We adjusted the numbers of 
neurons/mm2 to the ileum and colon circumference of the non-transgenic males to 
control for dilatation. 
We observed a strong decrease of ~50% in ganglia cell density in the proximal colon 
of end stage WT-7 males (249±59 vs. 436±94 per mm², p<0.0001) and a slight 
reduction in the G348C-4 line (359±43 vs. 436±,94 per mm², p<0.05) compared to 
non-transgenic littermates (Figure 13 B and C). 
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These results suggest a dysregulation of the enteric nervous system by a decreased 
number of ganglia cells due to human wild type TDP-43 overexpression, resulting in 
an altered gastrointestinal motility. Furthermore, the dysfunction of gastrointestinal 
motility appears to originate from the colon. 
Both TDP-43 hyperphosphorylation and an increased ubiquitin-staining in the CNS 
are frequent features of TDP-43 proteinopathies. In particular, phosphorylation of 
S409/410 of TDP-43 is consistently observed in all sporadic and familial forms of 
TDP-43 proteinopathies whereas ubiquitination might indicate abnormal 
accumulations of TDP-43 or other proteins [132]. Therefore, we analysed the tissue 
slide sets of the 6-month-old females with an antibody detecting phosphorylated 
TDP-43 at S409/410 sites and an antibody targeting ubiquitin. Ganglia cells showed 
no indication for phosphorylated TDP-43 species (Figure 14 A). Ubiquitin-positive 
staining was present in the ganglia of both transgenic animals and non-transgenic 
controls without aggregate formation. We concluded that the remaining ganglia cells 
in the colon of end stage WT-7 animals do not show features frequently seen in 
TDP-43 proteinopathies. 
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Figure 13. Human TDP-43 is expressed in the enteric nervous system of all human 
TDP-43 transgenic lines; in WT-7 mice, the ganglia cell density is reduced at the 
clinical endpoint. (A) Expression of human TDP-43 in ganglion cells in the myentric plexus 
of  ileum and colon of 6-month-old female mice shown by IHC with a human TDP-43 specific 
antibody. Human TDP-43 is mainly localized in the nucleus similar to the CNS apart from the 
NLS-mutants with cytoplasmic and nuclear localization. Scale bar 25µm (B) Azur II stained 
ganglia cells of the myenteric plexus. Scale bar 50 µm. (C) Counting of the ganglia cells and 
adjustment to the circumference ratio revealed a strongly reduced ganglia cell density in the 
WT-7 colon, a slight reduction in G348C-4 and no changes in M337V-5 compared to 
non-transgenic animals. 3 animals per group, 3-month-old. Data are analysed by One-way-
ANOVA with Dunnett´s test multiple comparisons; bars represent means ± SD; *p<0.05, 
****p<0.0001 
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A loss of ganglia cells can be associated with an increased acetylcholinesterase 
(AChE) activity, as demonstrated in Hirschsprung’s disease [148]. We performed 
enzyme histochemistry on frozen sections, covering the distal half of the small 
intestine and full colon and rectum of 3-month-old end stage WT-7 males and 
non-transgenic littermates using the “Swiss-role” technique. Both intestinal segments 
showed no evidence for an increased AChE activity in the WT-7 tissue 
(Figure 14 B). 
An alternate explanation for intestinal dysmotility is a lower density of the interstitial 
cells of Cajal (ICC) as seen in human slow transit constipation [149]. As pacemaker 
cells, they regulate the contraction of the intestinal smooth muscles by creating a 
periodical bioelectrical slow wave potential and therefor setting the basal electrical 
rhythm of the intestine. We performed immunofluorescence staining on frozen 
sections mentioned before using a c-Kit (CD-117) antibody, targeting a cytokine 
receptor abundant in ICCs. We observed comparable numbers of ICCs based on 
semi-quantitative assessment in the small intestine and colon of WT-7 males and 
non-transgenic controls. Furthermore, the localization of ICC subtypes in different 
tissue layers appeared to be unchanged (Figure 14 C). 
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Figure 14. TDP-43 overexpression in the ENS does not induce hyperphosphorylation, 
increased ubiquitin staining, increased AChE-activity or adisruption of the ICC 
pattern. (A) IHC staining for phosphorylated TDP-43 and ubiquitin in ganglion cells of the 
ileal and colonic myentric plexus of 6-month-old mice. None of the TDP-43 transgenic mice 
or the non-transgenic controls showed phospho-TDP-43-positve inclusions using the 
antibody TAR5p 1D3 for the phosphorylated sites pS409/410. Diffuse staining for ubiquitin 
indicated the existence of ubiquitin-mediated proteolysis without major differences between 
the strains. Ubiquitin-positive inclusions are not observed. (B) 3-month-old end stage WT-7 
males showno increase of acetylcholine esterase activity in “swiss role” frozen sections of 
the colon. (C) The distribution and density of intestinal cells of Cajal remains unchanged in 
the colon of 3-month-old end stage WT-7 males. Scale bar 25 µm. 
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7.6. Motor performance and cognitive tests 
Important clinical hallmarks of human TDP-43 proteinopathies are motor function 
deficiencies caused by a progressive loss of motor neurons in ALS or worsening 
cognitive capabilities resulting from a loss of cortical neurons in FTLD. The effect of 
human TDP-43 expression on the locomotive abilities was monitored in females of 
the WT-7 line ranging from 50 to 200 days of age and in females of the G348C-4 and 
M337V-5 lines within an age range of 300 to 600 days (Figure 15). The motoric tests 
persisted of rotarod, paw grip endurance and grip strength measurements and have 
been performed twice weekly (WT-7) or biweekly (G348C-4 and M337V-5). These 
tests cover motor coordination, endurance and the maximal muscle strength of the 
limb muscles. All monitored lines showed no locomotive constraint compared to 
non-transgenic littermates speaking against pathological changes in the motor 
nervous system. Notably, WT-7 animals in the early pathological stage marked by a 
swollen abdomen showed an unchanged motoric performance in the described tests. 
We performed two different tests to assess the cognitive abilities of WT-7, M337V-5 
and G348C-4 animals, novel object recognition test (NORT) and Y-maze, both 
supported by a video-based animal tracking system (Figure 16). The WT-7 animals 
were tested between the age of 56 to 146 days, the M337V-5 and G348C-4 between 
the age of 335 and 558 days. NORT based on the spontaneous tendency of rodents 
to spend more time exploring a novel object than a familiar one based on learning 
and recognition memory. The Y-maze consisted of three opaque arms arranged in a 
star-like manner, allowing to test for alterations in the spatial memory. 
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WT-7, M337V-5 and G348C-4 showed similar results for distance, immobile time and 
maximum speed when compared to non-transgenic controls in both NORT and Y-
maze. Furthermore, they showed no indication for a higher anxiety in the NORT 
environment (data not shown). We observed a couple of significantly altered results 
at different time points. In particular, we did not observe age dependent differences, 
speaking against an overall trend to cognitive decline during aging. However, these 
conclusion needs to be treated with caution because of high variability in the results. 
The absence of a motor phenotype or cognitive deficits made a major pathological 
alteration in the CNS unlikely. All transgenic lines were screened by IHC for 
presence of phosphorylated TDP-43 (Figure 17), reactive gliosis using GFAP as 
marker, activation of microglia and macrophages using IBA1 as marker and 
presence of ubiquitin aggregates in the CNS (Figure 18). Brain and spinal cord 
tissue was collected from males and females every second month of age starting 
with at one month of age up to the age of 12 or 13 months. Furthermore, sample 
tissue was collected from 24 or 25 months old geriatric mice. An exception was the 
short living WT-7 line with the oldest animals of 3 months (males) and 6 months 
(females) respectively. Consistent with results for motor dysfunction and cognitive 
impairment, none of the transgenic lines showed aggregates incorporating 
phosphorylated TDP-43 or ubiquitin-positive proteins. No evidence for 
neurodegeneration in the CNS with absence of astrogliosis and microgliosis was 
observed. 
Thus, the lethal WT-7 phenotype appears to be caused by toxic effects of TDP-43 
expression in the nervous system, suggesting that these neuron populations are the 
most vulnerable in our mouse model. 
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Figure 15. Motoric tests show no locomotive constraint in WT-7, M337V-5 and 
G348C-4 females compared to non-transgenic littermates. Forced motor activity was 
tested with the rotarod performance test. Paw grip endurance (PAGE) as well as the grip 
strength test show no constraints regarding the endurance or maximum applicable force of 
the limbs. n=13 for transgenic WT-7 females, n=14 for non-transgenic WT-7 littermates; n=9 
for M337V-5 females, n=8 for G348C-4 females, n=6 for non-transgenic littermates of the 
same age (3x M337V-5 nontg; 3x G348C-4 nontg); Data are analysed by Two-way-ANOVA 
with Sidak multiple comparisons, bars represent means ± SD; *p<0.05, **p<0.01, 
****p<0.0001. 
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Figure 16. Behavioural tests reveal no cognitive deficits in WT-7, M337V-5 and 
G348C-4 animals compared to non-transgenic animals. (A) No significant cognitive 
deficit was observed in WT-7 animals of both genders tested by a novel object recognition 
test (NORT). (B) WT-7 animals showed the same preference for a new arm in a left–right 
discrimination paradigm of a Y-maze as non-transgenic controls. (C and D) Aged M337V-5 
and G348C-4 animals show the same cognitive performance in the NORT and Y-maze as 
non-transgenic controls. n=7 for transgenic WT-7 (3 males / 4 females), n=14 for 
non-transgenic WT-7 littermates (6 males / 8 females); days 125 and 141 do not include 
WT-7 males. n=13 for M337V-5 (9 females; 4 males), n=15 for G348C-4 (7 males / 8 
females), n=16 for non-transgenic littermates of the same age (11 males / 5 females); Data 
are analysed by One-Sample t-test against 1 (NORT) or 50 (Y-maze), one-tailed, bars 
represent means ± SD; *p<0.05. 
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Figure 17. TDP-43 is not hyperphosphorylated in our human TDP-43 mouse models. 
IHC with an antibody detecting phosphorylated TDP-43 sites at the C-terminus (pS409/410) 
on brain and spinal cord tissue of 3-month-old males. None of the transgenic lines show 
nuclear or cytoplasmic inclusions positive for phosphorylated TDP-43, a consistent feature in 
all sporadic and familial forms of TDP-43 proteinopathies. Scale bar: 20 µm. 
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Figure 18. Brain and spinal cord of human TDP-43 expressing mice show no 
indications for neuroinflammation or impaired protein degradation. IHC with an 
antibody against IBA1, a marker for microgliosis, GFAP, a marker for astrogliosis, and 
ubiquitin. 3-month-old end stage WT-7 males and aged males of the other human TDP-43 
transgenic lines show no signs of neurodegeneration in the CNS compared to 
non-transgenic animals. There is no evidence for an accumulation of ubiquitin-positive 
protein aggregates, speaking against an inhibition of protein degradation or an increase of 
aberrant protein species. Scale bar: 20 µm. 
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7.7. Gender-dependent life span discrepancy in WT-7 animals is estrogen 
dependent 
WT-7 mice showed premature lethality with a striking gender difference for survival 
times (average life span: 103±16.7 days compared to 157.5±33.4 days; p<0.0001) 
(Figure 11 C). 
A possible explanation for the gender difference would be a beneficial or detrimental 
effect of sex specific hormones. To investigate this, we castrated WT-7 males and 
ovariectomized WT-7 females shortly before sexual maturation at the age of 30 to 35 
days. The mice were closely monitored and euthanized when the terminal stage was 
reached, defined by the WT-7 control sheet (Table 2). Ovariectomized WT‐7 females 
showed a reduced life span compared to sham operated WT-7 control females 
(mean age at terminal endpoint: 113.4±10.9 days vs. 128.8±17.3 days, p=0.0114) 
(Figure 19 A). In contrast, castration of WT‐7 males did not alter the life span 
compared to sham operated WT-7 control males (mean age at terminal endpoint: 
109.9±24.2 days vs. 100.9±11.9 days, p=0.4170) (Figure 19 B). The groups of sham 
operated mice included of 12 animals of females and males respectively. 6 sham 
females and 7 sham males obtained an additional placebo pellet without hormones 
to exclude a general effect of subdermal implants on the life span. The life span of 
sham operated mice with a placebo pellet was equal to mice with sham surgery 
without placebo pellet (mean age at terminal endpoint females: 134.5±19.91 vs. 
123.20±13.67 days, p=0.2771; mean age at terminal endpoint males: 97.86±13.70 
days vs. 105.20±8.44 days, p=0.3160; t-test).  Therefore, all sham operated animals 
with placebo pellet were treated as sham operated mice for further investigations. 
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Figure 19. Gender-depended life discrepancy is mediated by female sex hormones (A) 
Ovariectomy of human TDP‐43 WT‐7 females leads to a reduced life span compared to 
sham operated WT-7 females (mean life span: 113.4±10.9 days to 128.8±17.3 days; n=12; 
SD, p=0.0114). (B) In contrast, castration of human TDP‐43 WT‐7 males by orchiectomy 
does not alter the lifespan compared to sham operated WT-7 males (mean life span: 
109.9±24.2 days to 100.9±11.9 days; n=11/12; SD, p=0.4170).  Data are analysed by Log-
rank (Mantel-cox) test; *p<0.05 
The results from the previous experiments argue for a beneficial effect of female sex 
hormones without major influence of male sex hormones. To further address the role 
of female sex hormones, we implanted subcutaneous pellets releasing 17β-estradiol, 
the most potent female sex hormone [150], in ovariectomized WT-7 females. The 
pellets provided a constant hormone substitution for 90 days and have the 
advantage of lower stress levels compared to daily injections and a higher 
consistency then dilution in drinking water. Two concentrations were administered: 
high dose (HD) 17β-estradiol pellets (0.002 mg/day) pellets or low dose (LD) pellets 
(0.0004 mg/day). The 17β-estradiol concentrations have been selected according to 
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published experiments using pellets of the same manufacturer to avoid over- or 
underdosage [151-154]. To maintain treatments over a 4 months period, animals 
were delivered a second pellet 3 months after the initial pellet if necessary. Castrated 
human TDP‐43 WT‐7 females with 17b‐estradiol supplement showed a trend 
towards a dose dependent life span extension compared to castrated animals, but 
do not reach the life span of mice after sham surgery (Figure 20). 
 
Figure 20. 17β-estradiol treated castrated females show a trend towards a life 
extension. 17β-estradiol supplemented castrated females showed a trend towards a dose 
dependent life span extension compared to castrated females without treatment (mean life 
span: castrated females 113.4±10.9 days n=12; castrated females with low dose supplement 
116±14.5 days n=6; castrated females with high dose supplement 117.8±18.6 days n=11; 
females with sham surgery: 128.8± 17.3 days n=12; SD). Data are analysed by Log-rank 
(Mantel-cox) test. 
The uterus wet weight was used as a control for a successful removal of sex-
hormone releasing tissue and hormone supplementation in female mice 
(Figure 21 A and B). Ovariectomized WT‐7 females showed a significantly reduced 
uterus weight compared to sham operated females, lacking the growth stimulus of 
endogenous sex hormones (13.6±3.4 mg vs. 23.73±4.5 mg, p<0.0001) 
(Figure 21 A). 17β-estradiol treatment of ovariectomized WT‐7 females resulted in a 
significant increase of uterus wet weight compared to sham operated females. High 
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dose treated females had the highest uterus weight, indicating that the uterine cells 
underwent hypertrophy and/or hyperplasia following extensive 17β-estradiol 
exposition (mean uterus wet weight: females with sham surgery 23.73±4.5 mg, 
castrated females with high dose supplement 47.9±14.3 mg, castrated females with 
low dose supplement 27.8±18.2 mg) (Figure 21 B). The results demonstrate that the 
17β-estradiol releasing pellets have reconstituted the basal hormone status seen in 
mice who were undergoing sham surgery. However, both pellet supplemented 
cohorts of ovariectomized animals showed a higher variability in the uterus wet 
weight, speaking for some variability in hormone release. Likewise, constant 
hormone supply is not able to reconstitute the complexity of the estrous cycle.  
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Figure 21. Increased uterus weight indicates successful 17β-estradiol administration 
in castrated WT-7 females. (A) Measurements of the uterus wet weight after death show a 
decreased uterus weight in females with ovariectomy compared to sham operated female 
controls: 13.6±3.4 mg vs. 23.73±4.5 mg. Data were analysed by t-test, ****p<0.0001. (B) 
High dose treatment with 17β-estradiol resulted in an increased uterus weight compared to 
sham operated females without treatment. (castrated females n=8, females with sham 
surgery n=7, castrated females with high dose supplement n=12, castrated females with low 
dose supplement n=6) Data are analysed by One-way-ANOVA with Tukey’s test multiple 
comparisons; bars represent means ± SD; **p<0.01, ****p<0.0001 
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8. Discussion 
Over the last decade, TDP-43 has been identified as a major pathological protein in 
ALS and FTLD-TDP, however the mechanism leading to cell death and its exact 
function in the CNS remain unclear. Transgenic mouse models might be powerful 
tools to explore the mechanisms in TDP-43 proteinopathies resulting in a fatal 
clinical phenotype in humans. However, results from transgenic mouse models so far 
are quite inconsistent; no model fully recapitulates human pathology. The 
interpretation of results is hampered by the fact that TDP-43 is a tightly 
autoregulated protein and that reported phenotypes are strongly linked to expression 
levels of TDP-43 transgenes. Furthermore, several studies do not include 
comparison of wild type TDP-43 and TDP-43 with human pathogenic mutations, 
leaving important questions unanswered. 
In order to unravel the pathomechanisms underlying TDP-43 proteinopathies, we 
generated and analysed TDP-43 transgenic animals expressing four different 
constructs covering overexpression of wild type human TDP-43, the ALS-associated 
mutation M337V and G348C4 as well as an altered nuclear localisation signal, 
inducing cytoplasmic translocation with comparable expression levels, that allowed 
us to address the specific questions on weather overexpression of wild type TDP-43 
is toxic, weather fALS-associated mutations in the human TDP-43 are associated 
with a toxic gain-of-function and weather increased levels of cytoplasmic TDP-43 are 
sufficient to induce toxicity.   
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8.1. Comparable levels of wild type TDP-43 are more toxic than TDP-43 with 
human pathogenic mutations 
Comparing mouse lines expressing human wild type TDP-43 or human TDP-43 with 
pathogenic mutations with comparable expression levels as well as the expression 
patterns revealed striking differences with the wild type line WT-7 developing a 
pathological lethal phenotype in contrast to lines expressing different human 
pathogenic mutations (M337V and G348C). 
The phenotype in the WT-7 line consists of a sex-dependent premature death (mean 
age at death: 133.6±38.7 days) originating from a gut motility deficit, related to 
gastrointestinal alterations including an increased intestinal diameter, an ileal smooth 
muscle thickening and a loss of enteric neurons in the myenteric plexus in the colon 
of end stage mice. Neither motor deficits nor cognitive impairments were observed 
and end stage WT-7 mice developed no pathological changes like TDP-43 
aggregation, ubiquitination and phosphorylation, astrocytosis or activation of 
microglia in the CNS. 
Demonstrating that the transgenic human wild type TDP-43 and the mutated human 
TDP-43 reduce the levels of endogenous murine TDP-43 by an autoregulatory 
mechanism in a comparable way in our mouse lines, an effect due to loss of 
endogenous TDP-43 is unlikely to explain the difference. Moreover, both WT-7 and 
the mutant mouse lines express transgenic TDP-43 in the enteric nervous system 
speaking against an effect of differential expression patterns. 
Another potential explanation for a unique phenotype in a single transgenic line 
could be an integrational artefact, disrupting an endogenous genomic DNA 
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sequence unrelated to the actual transgene. However, Wegorzewska et al. created a 
mouse model expressing human TDP-43 with the disease-associated mutation 
A315T (PrP-TDP-43 A315T) causing a premature death with a mean survival of 153 
days [105]. Surprisingly, it took 2 years to discover the main cause of death: 
PrP-TDP-43 A315T mice develop gastrointestinal complications, associated with 
TDP-43 aggregation, vacuolization within the myentric plexus and a progressive 
neurodegeneration, mainly restricted to the colon [155-157]. The phenotypical 
similarity of WT-7 and PrP-TDP-43 A315T argues strongly against an integrational 
artefact. 
Thus, the striking differences in the phenotype in our lines by expressing comparable 
levels of wild type human TDP-43 or mutant TDP-43 suggests a more toxic role of 
wild type TDP-43 and thereby argues against a gain-of-function mechanism of 
mutations. 
8.2. Expression of wild type TDP-43 can induce a gastrointestinal phenotype 
The WT-7 line is the first TDP-43 mouse model demonstrating a gut motility defect 
upon transgenic expression of wild type TDP-43. The previously described 
PrP-TDP-43 A315T mouse model expressing human TDP-43 with the disease-
associated mutation A315T also develops a lethal gut motility defect [155-157]. 
However, some obvious differences show up: Wegorzewska et al. reported a 3-fold 
higher expression of transgenic human TDP-43 in the CNS of the 
PrP-TDP-43 A315T line compared to endogenous TDP-43 in non-transgenic 
animals, which was later confirmed  by Guo et al. [105, 156]. The expression levels 
of transgenic human TDP-43 in the PrP-TDP-43 A315T line are approximately 3-fold 
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higher than in our WT-7 line, as the total TDP-43 levels in the brain remained 
unchanged between WT-7 mice and non-transgenic littermates. It must be pointed 
out that the expression levels in the intestine were not estimated.  
This finding suggests that pathological mutations in TARDBP might be partial 
loss-of-function mutations, so higher expression levels are needed compared to fully 
functional wild type TDP-43 to induce a similar toxic effect most likely due to altering 
the normal homeostasis of TDP-43 with downstream dysregulation of RNA 
processing. Furthermore, our results challenge the conclusions from the previous 
studies that TDP-43 mutations are associated with a toxic gain-of-function 
mechanism. 
The involvement of the enteric nervous system in ALS and FTLD is not well 
examined; a single study reported gastrointestinal motor dysfunction in the majority 
of ALS patients, independent of bulbar involvement, upper motor neuron involvement 
or disease duration [158]. Furthermore, question surveys showed an increased rate 
of self-reported constipation [159]. Nevertheless, gastrointestinal dysfunction is a 
frequent feature in other neurodegenerative diseases, such as Dementia with Lewy 
bodies (DLB) [160] and Parkinson´s disease (PD) [161, 162]. Notably, recent reports 
suggest a link between these two diseases and TDP-43 pathology as more than 
50% of DLB-patients show pathological phosphorylated TDP-43 in the CNS [163] 
and genetic data support a potential role of TDP-43 mutations in clinical PD [164, 
165]. Furthermore, concomitant expression of wild type human TDP-43 and mutant 
α-synuclein by crossing transgenic mice indicate a synergistic role of both proteins 
resulting in more severe loss of dopaminergic neurons [166]. The co-occurrence of 
TDP-43 pathology in different neurodegenerative diseases characterized by 
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gastrointestinal dysfunction might indicate an involvement of TDP-43 hitherto not 
noticed. 
The gut phenotype of the WT-7 line resembles some features of the human disorder 
Hirschsprung´s disease (HD). HD is a congenital disorder, effecting about 1 in 5.000 
new-borns. It is characterized by the absence of ganglia cells in the myentric plexus 
in parts or all of the large intestine, resulting in a severe constipation and distended 
bowel due to a non-motile colon [167]. Similar to FTLD and ALS, HD is related to 
mutations in several genes inducing aganglionosis with many of them displaying 
incomplete penetrance [168]. Most of known HD-associated genes encode members 
of two main signalling pathways: the RET (proto-oncogene rearranged during 
transfection) and EDNRB (endothelin receptor, type B) pathways. Both pathways 
regulate survival, differentiation, migration, and proliferation of neural crest-derived 
cells [169]. An investigation into the relationship between TDP-43 and RET pathway 
or EDNRB pathway is to consider as TDP-43 overexpression might interfere with 
these pathways in TDP-43 transgenic mouse models. Furthermore, differences in 
the vulnerability of cells in the myenteric plexus of the colon compared to other 
intestinal segments might explain the restriction to this specific region in HD. For 
example, diminished Ret expression in a HD mouse model compromised neuronal 
survival in the colon without detectable neuronal loss in the small intestine [170]. A 
higher vulnerability for TDP-43 mediated toxicity in enteric neurons in the colon could 
explain the development of a clinical phenotype in the intestine prior detectable 
pathological changes in the CNS in our TDP-43 WT-7 line. 
The intestinal system can be used as a model to study general functions of TDP-43 
due to its diverse cell composition similar to the CNS and a high accessibility for drug 
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administration. However, it remains questionable if the ENS provides a model for 
human TDP-43 proteinopathies lacking key features of human disease progression. 
8.3. Wild type TDP-43 expressing mouse models vary in phenotype  
Several TDP-43 animal models were generated in recent years to investigate the 
consequences of TDP-43 overexpression in vivo [171]. Expression of wild type 
human TDP-43 under the control of the murine PrP-promotor was studied by two 
research groups [104, 172].  
Stallings et al. generated 13 wild type human TDP-43 expressing mice with 9 
founders developing a motor phenotype characterized by weakness, spasticity and 
reduced spontaneous movements with early premature death ranging from 12 to 
34 days, correlating with the TDP-43 expression levels in the spinal cord [172]. Motor 
abilities were studied by a gait analysis and grip strength measurements. Affected 
founders also manifested a progressive weight loss prior death. Spinal cord 
pathology was observed in at least one founder with motor neurons in ventral horn 
appearing hyalinised with amorphous nuclear and cytoplasmic architecture. Three 
founders survived into adulthood and were established as transgenic mouse lines. 
Surprisingly, the wild type line with the highest spinal cord expression did not 
develop a motor phenotype up to 11 month despite the rare appearance of neurons 
with an increased diffuse ubiquitin staining. Another line with a lower expression in 
the spinal cord showed a late onset progressive motor phenotype resulting from a 
progressive myopathy in the skeletal muscle, correlating with increased TDP-43 
expression in the muscles. Stallings et al. concluded that overexpression of TDP-43 
in vivo can lead to the development of progressive motor syndromes in mice with 
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pathology sharing some similarity to TDP-43 proteinopathies and that a strong 
TDP-43 overexpression outside of the CNS may also yield disease. Considering our 
results for the human TDP-43 WT-7 line, a more detailed cause of death analysis, 
quantification of the total TDP-43 levels and determination of TDP-43 expression 
beyond CNS and skeletal muscle are advised.   
Xu et al. generated a single mouse model with wild type human TDP-43 under the 
control of the murine PrP-promotor and were able to maintain hemizygous and 
homozygous breeding [104]. Aged hemizygous TDP-43 mice were phenotypically, 
histologically, and immunohistochemically indistinguishable from aged 
non-transgenic controls despite a 1.9-fold increase of total TDP-43 in the brain. The 
homozygous TDP-43 mice showed a 2.5-fold increase compared to non-transgenic 
controls. Xu et al. reported TDP-43 truncation as well as intranuclear and 
cytoplasmic aggregates that were immunopositive for phosphorylated TDP-43 in the 
CNS. However, human TDP-43 was not ubiquitinated despite increased cytoplasmic 
and nuclear ubiquitin levels. Reactive gliosis as well as axonal and myelin 
degeneration were observed in the spinal cord of end stage mice together with an 
abnormal aggregation but without a loss of neurons via apoptosis. Gait abnormalities 
occurred and were determined by a motorized treadmill with a video capture system. 
Homozygous TDP-43 mice died premature with 1 to 2 month of age unable to right 
themselves. The final cause of death was not determined. The human TDP-43 
expression was highest in the brain and spinal cord, with moderate levels in the 
testis and spleen, and low levels in other tissues, such as the heart, liver, kidneys 
and stomach. A gastrointestinal phenotype cannot be excluded as expression data 
for the intestine are missing. Xu et al. showed that even small differences in the 
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expression level of wild type human TDP-43 result in major differences in the 
phenotype. 
These studies and our results indicate that wild type TDP-43 expressed under 
control of the murine PrP-promotor is able to induce pathological phenotypes. 
However, a direct comparison is difficult due to different expression levels resulting 
in a huge variability in the reported phenotypes. 
8.4. Motoric and cognitive phenotypes in TDP-43 transgenic mice correlate 
stronger with expression level rather than pathological mutations   
Our transgenic mouse lines WT-7, M337V-3, M337V-5 and G348C-4 did not exhibit 
cognitive or motoric alterations or obvious signs of neurodegeneration in the motor 
system, in contrast to some reports on previously generated TDP-43 rodent lines 
expressing wild type human TDP-43 or variants with pathogenic mutations [104-106, 
111, 116, 117, 172-174]. However, reported onset and manifestation varies greatly 
between the reported TDP-43 models. Differentiation between important TDP-43-
mediated alterations emulating the human disease situation and secondary factors is 
complicated for various reasons. At first, even a small increase of the total TDP-43 is 
sufficient to induce lethal phenotypes. Comparison of transgenic mice expressing 
TDP-43 under different promoters is difficult due to differences in the expression 
pattern and expression onset during development. Secondly, TDP-43-mediated 
toxicity is strongly influenced by the genetic background. For example, congenic 
PrP-TDP-43 A315T with a congenic C57BL/6J background die significantly earlier by 
the gastrointestinal phenotype than mice of various mixed genetic backgrounds 
[157]. Likewise, some conclusions made in earlier publications have to be treated 
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with caution. For example, the original characterization of the PrP-TDP-43 A315T 
line missed the fact that mice die premature due to gastrointestinal complications 
rather than CNS and described motoric changes were not fully recapitulated in 
follow-up studies on these mouse lines [105, 155].  
Tests for cognitive impairments and behavioral changes like Barnes maze task, 
Morris water navigation task, open field test or active and passive avoidance tests 
were only performed in a minority of reports. Swarup et al. generated mice 
expressing wild type human TDP-43, A315T or G348C mutant forms under control of 
the human TARDBP-promoter [173]. All three transgenic mouse models exhibited 
impaired learning and memory capabilities during ageing, as well as motor 
dysfunction. These lines expressed comparable levels of human TDP-43 mRNA, but 
the total TDP-43 protein levels were not measured. Impaired learning and memory 
capabilities and motor impairments were also reported for three transgenic mouse 
lines expressing mouse wild type TDP-43 under control of the CaMKII-promotor in 
the forebrain, resulting in a 2-fold increase of total TDP-43 compared to 
non-transgenic animals [117]. Notably, TDP-43 expression induced impaired 
cognitive function at 2 month of age and motor dysfunction in the 6 month-old 
transgenic mice. In contrast, PrP-TDP-43 A315T animals showed not symptoms of 
cognitive decline prior death due to the gastrointestinal motility defect [175]. 
Current data argue that the reported motoric and behavioural changes are largely 
depending on the overexpression level of TDP-43, reaching a neurotoxic threshold. 
Our transgenic mice showed no motoric and behavioural changes either because the 
cellular TDP-43 levels in the CNS remained below this neurotoxic threshold or the 
gastrointestinal phenotype preceded CNS-related changes. 
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The current overexpression models for disease-associated mutations are not be able 
to address further questions as changes in the expression level strongly influence 
the phenotypical outcome. More sophisticated knock-in models are needed to 
investigate the phenotypical changes induced by disease-related mutations in the 
endogenous TDP-43 under native expression levels. 
8.5. Increased cytoplasmic TDP-43 is not sufficient to induceTDP-43 
aggregation and toxicity 
Cytoplasmic TDP-43 accumulation with TDP-43 nuclear clearance is a hallmark of 
TDP-43 proteinopathies. Under normal conditions, TDP-43 is mainly localized in the 
nucleus, presumably within specific nucleoplasmic domains required for its normal 
function such as transcriptional repression, pre-mRNA splicing and mRNA transport 
and stabilization [176]. These observations led to the hypothesis that increased 
cytoplasmic TDP-43 levels are potentially toxic due to abnormal interactions. 
In order to address this hypothesis in vivo we generated the transgenic mouse lines 
NLS-4 and NLS-6 expressing human TDP-43 protein with a modified NLS sequence 
resulting in a decreased nuclear uptake. We observed a diffuse cytoplasmic 
distribution of human TDP-43 without aggregate formation, neurodegeneration or a 
clinical phenotype. Our results show that TDP-43 with a mutated NLS sequence is 
partially redistributed to the cytoplasm in vivo, but that increased levels of 
cytoplasmic TDP-43 are not sufficient to induce TDP-43 aggregation, sequestering of 
endogenous TDP-43 and/or a neurodegenerative phenotype in vivo. 
Other groups have also addressed the question whether cytoplasmic TDP-43 causes 
protein aggregation and neurodegeneration in rodents: Igaz et al. generated mice 
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expressing human TDP-43 with mutated controlled by an inducible Tet-Off system in 
combination with forebrain-specific CaMK2α promoter elements [111]. Transgene 
expression was inhibited until 28 days of age. They observed a progressive neuron 
loss in the NLS lines depending on the general expression strength and the selective 
vulnerability of particular brain regions such as the dentate gyrus. Cytoplasmic 
expression of human TDP-43 triggered variable accumulation of 
hyperphosphorylated and ubiquitinated human TDP-43 with mutated NLS in 
cytoplasmic aggregates. However, the paucity of aggregates in the low expressing 
line indicated that cytoplasmic inclusions were not required for neuron death. Dayton 
et. al used a different approach by transducing rats at postnatal day 1 with 
intravenous administration of an adeno-associated virus (AAV9) gene transfer 
method in the temporal vein, resulting in a uniform expression of human TDP-43 with 
a mutation in the NLS controlled by the strong CMV-promotor [112]. Two different 
AVV9 dosages were used. Transduced animals of the high dose AVV9 group 
developed a motor impairment within 2 weeks, determined by a hind limb escape 
reflex test, rotarod and open field test, whereas only 2 of 8 low dose treated rats 
developed minor signs of limb impairments. However, Dayton et al. were unable to 
discern any evidence of ubiquitin or p62 immunopositive cytoplasmic aggregates in 
intravenously transduced rats. Noticeably, with more concentrated AAV9 stereotaxic 
brain injections, rare TDP-43 aggregates were induced.   
There are some explanations for the different phenotype compared to our mouse 
lines NLS-4 and NLS-6. First, our transgenic mice show a low expression level with 
total TDP-43 levels quite comparable to non-transgenic mice in contrast to Igaz et al. 
reporting an 8 to 9-fold overexpression of total TDP-43 in the forebrain of their NLS-
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lines. Dayton et al. reported a consistent 2-fold overexpression of total TDP-43 in the 
cervical and lumbar spinal cord in intravenously transduced rats using high dose 
AVV9 titers. In our NLS-lines, the total TDP-43 levels remained unchanged. Second, 
neuronal vulnerability to TDP-43 overexpression is depending on timing of induction 
due to a high sensitivity of neurons during early development [118]. Gene expression 
controlled by mouse prion promotor is reported at earliest at embryonic day 13.5, 
speaking for considerable differences between the model systems [177]. 
Moreover, in contrast to cell culture models of NLS mutations, all NLS rodent models 
described show an incomplete cytoplasmic localization of transgenic TDP-43 with 
NLS mutation with various proportions of transgenic TDP-43 also in the nucleus, 
possibly explained by dimerization of TDP-43 with NLS mutation and wild type 
TDP-43 and subsequent nuclear uptake [76, 178]. This raises the question if 
reported neurotoxic effects in the above mentioned mouse rodent models might be 
induced by cytoplasmic TDP-43 or result from a small but fatal increase of total 
TDP-43 in the nucleus. 
Reports from other in vivo NLS models are ambiguous whether there is a link 
between increased cytoplasmic TDP-43 and toxic effects: Caenorhabditis elegans 
developed a neurodegenerative phenotype by expression of wild type human 
TDP-43, whereas expression of human TDP-43 containing point mutations in NLS 
resulted in cytoplasmic accumulation of both diffuse and aggregated human TDP-43 
without neurotoxic effects [179]. In Drosophila melanogaster, expressing either wild 
type human TDP-43 or TDP-43 with mutations in the NLS is neurotoxic [114, 180]. 
In vitro models developed pathological phenotypes, but also missed some key 
features of TDP-43 proteinopathies: Winton et al. showed that a mutated NLS 
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restricts human TDP-43 distribution to the nucleus and leads to cytoplasmic retention 
of the endogenous TDP-43 in TDP-43 aggregates within transfected cell lines [109]. 
These aggregates also recapitulated the biochemical signature of pathological 
TDP-43 in FTLD-TDP and ALS, including a high molecular weight smear of 
ubiquitinated TDP-43 and C-terminal TDP-43 fragments. However, cellular toxicity 
was not reported. In contrast, Barmada et al. reported a higher cumulative risk of 
death in primary cultures of rat cortical neurons after transfection with NLS-mutant 
human TDP-43 compared to wild type TDP-43 transfected cells [181]. The formation 
of ubiquitin-immunopositive, detergent-insoluble inclusion bodies were observed but 
not necessary for the toxicity. 
Our results for the NLS lines indicate that increased levels of  cytoplasmic TDP-43 
per se are not sufficient to induce neurodegeneration and support the idea of a 
multiple-hit-model of TDP-43 inclusion body formation [126]. This model implies that 
TDP-43 inclusion body formation depends on cascade of cellular events starting with 
cytoplasmic mislocalization (first hit) and an independent second hit inducing the 
formation of cytoplasmic aggregates that may sequester TDP-43, disrupt RNA 
processing and initiate neuron degeneration. A proposed step in this cascade is the 
formation of stress granules (SG), dense aggregations composed of proteins and 
RNA, initiated by environmental stress triggers, as a precursors for pathological 
protein aggregates [182, 183]. Cytoplasmic TDP-43 inclusions have been shown to 
colocalize with several SG markers in cultured cells and primary neurons in 
response to cellular stress as well as in post-mortem samples from ALS and FTLD 
patients [184]. However, only a single study claimed that withdrawal of the stressor 
lead to removal of SGs while TDP-43 positive aggregates remained present [185], 
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whereas other studies did not observe persistent TDP-43 aggregates after SGs 
dissociation [183]. 
A different potential modifier of initial TDP-43 aggregation and propagation is an 
intrinsic part of the TDP-43 protein structure: recent studies showed that the 
C-terminal domain, in addition to mediating protein-protein interactions, has 
properties of a Q/N-rich prion domain [63, 64, 186, 187]. Transduction of cultured 
cells with insoluble recombinant TDP-43 fibrils triggered the aggregation of 
intracellular TDP-43 proteins, becoming sarkosyl-insoluble and ubiquitinated [65]. 
Insoluble TDP-43 aggregates from diseased brains showed the same prion-like 
properties by inducing seed-dependent and self-templating aggregation of 
intracellular TDP-43 in the neuroblastoma cell line SH-SY5Y transfected with human 
TDP-43 [69]. The cells with intracellular TDP-43 released TDP-43 aggregates via 
exosomes, propagating phosphorylated TDP-43 aggregates between cultured cells, 
raising the question of a potential transmission via exosomes as an intermediate 
step during human pathogenesis, a concept already proposed earlier [188]. 
Our NLS-lines will be valuable tools to further investigate the proposed two-hit-model 
as well as the role of seeding in TDP-43 proteinopathies as cytoplasmic localization 
might represent the initial step in a fatal molecular cascade. By applying cellular 
stressors or insoluble TDP-43 species on primary cortical neurons or organotypic 
slice cultures of our NLS strains, it can be tested whether they are able to induce 
pathological changes similar to those seen in TDP-43 proteinopathies. 
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8.6. Role of estrogen in the phenotype of the TDP-43 expressing mouse line 
WT-7 
The observed life span of male and female WT-7 animals was significantly different 
with 103±16.7 days in males compared to 157.5±33.4 days in females. Notably, 
epidemiological studies have shown that both the incidence and prevalence of ALS 
are greater in men than in women [189]. Female sex hormones might play a 
beneficial role as women who develop ALS have often had a later menarche and 
earlier menopause than healthy controls [190] with ALS incidence shifting from a 
male/female ratio of 4:1 in the second decade to 1:1 at ages above 60 years [191]. 
We abolished sex hormone release in both genders of WT-7 by ovariectomy or 
castration prior maturation and later partially reconstituted the hormone status in 
ovariectomized WT-7. 
By abolishing sex hormone release in both genders of WT-7 by ovariectomy or 
castration prior maturation, we observed a significantly earlier disease onset in 
ovariectomized WT-7 females compared to sham-operated controls, whereas 
castration of WT‐7 males did not alter disease onset compared to sham-operated 
controls. Together with the partial rescue upon 17β-estradiol supplementation in 
ovariectomized WT-7 females, our data exclude a detrimental effect of androgens 
and provide strong evidence for a beneficial effect of female sex hormones in our 
mouse model in line with the postulated beneficial role of female sex hormones in 
ALS patients.  
Notably, a similar striking sex difference was observed in the human TDP-43 A315T 
mouse line [105]. In accordance with our data, a strongly reduced survival by 
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ovariectomy has been reported in this line with a reduced life span of 105 days 
compared to 200 days in sham operated controls [157]. Castration of TDP-43 A315T 
males resulted in a minor lifespan decrease with a median survival of 91 compared 
to 102 days in sham operated controls. A recent study further investigated the role of 
progesterone in this mouse model, showing a reduced rate of loss of locomotor 
control in progesterone treated males but no significant increase in survival of the 
mice [192]. Thus, these and our data indicate a beneficial effect of female gonadal 
hormones in TDP-43 animal models. 
The presence of sex differences and the beneficial role for female sex hormones are 
also reported for SOD1 mouse models of ALS [189]: ovariectomy  of  human SOD1 
G93A transgenic animals did not alter the onset age of the disease while reducing 
the lifespan in females by 7 days and making it comparable to that of the male 
transgenic mice [154]. Treatment of ovariectomized females with 17β-estradiol did 
not delay the onset of disease, but prevented progression of ALS motor dysfunctions 
for a limited time window and rescued the lifespans in ovariectomized females. A 
prior study observed significant acceleration of disease progression by ovariectomy 
and a significantly delayed disease progression by 17β-estradiol treatment in the 
same model, but failed to rescued the lifespans in ovariectomized females, 
proposing an additional effect of progesterone [193]. However, the conclusions 
drawn from the studies need to be treated with caution as the differences are small 
and other groups did not observe a detrimental effect in gonadectomised SOD1 
G93A mice [194]. 
Female sex hormones are also positive modifiers in drug treatment experiments 
using the SOD1 animal models [194-197]. The involved cellular pathways are still 
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unknown, but recent publications revealed that deficiency in Pgc-1α, a transcriptional 
co-activator mediating the cellular response to metabolic demands, resulted in male-
specific earlier disease onset in SOD1 G93A mouse models [198-200]. Strikingly, 
SNPs in the brain-specific promoter region of PGC-1α do also influence the survival 
of men in clinical cohorts, but not in the female population [201]. In contrast to the 
results in the SOD1 mouse models, SOD1 G93A transgenic rats showed no 
significant effect of gonadectomy on disease onset and progression [194, 202]. 
Further investigations are needed to dissect the specific role of individual female 
gonadal hormones for a delayed disease onset, slowed progression and increased 
survival. 
17β-estradiol is widely acknowledged as the most potent form of estrogens, which 
exert different functions such as neurotropic factors or neuroprotective agents. 
Binding of estrogens to estrogen receptors can induce both a genomic effect by an 
altered transcription as well as a fast non-genomic response modulating different 
cellular pathways [203]. 17β-estradiol was used as neuroprotective supplement for in 
vitro motor neuron cultures [204-206]. It can also induce an indirect neuroprotective 
effects in motor neuron cultures by increasing the GDNF secretion in astrocytes. 
This observation is worth mentioning as marked up-regulation of estrogen receptor α 
was observed in spinal astrocytes of amyotrophic lateral sclerosis patients [205]. 
Notably, also gastrointestinal motility is considerably modified by sex hormones. The 
absence of estrogen inhibits the gastric emptying and delays gastrointestinal transit 
in ovariectomized female rodents, whereas estrogen and progesterone treatment of 
males delayed the gut emptying; by contrast testosterone has no influence on gastric 
emptying or gastrointestinal transit [178, 207-210]. Estrogen receptor α and β are 
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both expressed in neurons in the myenteric plexus of rat and mouse [211, 212]. 
There is strong evidence for a similar relationship in humans as idiopathic 
constipation is higher in women of reproductive age than postmenopausal women or 
men, suggesting that female sex hormones influence gastrointestinal motility [213, 
214]. The colonic transit time also correlates with the menstrual cycle as it is 
significantly extended during the luteal phase, characterized by high estrogen levels 
[215]. 
Due to the diverse effects of estrogens, there are different possible explanations for 
the protective effect in the WT-7 mouse line: estrogen might either exert a 
neuroprotective effect on neurons in the myenteric plexus and therefore delaying the 
neurotoxic effect of TDP-43 overexpression or alter the excitability of subpopulations 
of neurons resembling effects in the CNS [216]. Additionally, an indirect effect 
unrelated to the myenteric nervous system remains possible as estrogen reduces 
the excitability of myocytes in the intestine muscle tissue, mediated by a rapid non-
genomic mechanism activating K+ channels or inhibiting Ca2+ channels [217, 218]. 
8.7. Final conclusions 
Our mouse lines overexpressing different human TDP-43 proteins represent the 
most diversified population of TDP-43 models expressing quite comparable levels 
different TDP-43 constructs on a pure genetic background. 
In contrast to transgenic expression of human TDP-43, neither overexpression of 
TDP-43 with ALS-associated mutations nor TDP-43 with forced cytoplasmic 
localization was sufficient to induce a pathological in our models, thereby arguing 
against a toxic gain-of-function mechanism of human pathogenic mutations and 
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increased levels of cytoplasmic TDP-43. Particularly NLS lines will be valuable tool 
to further address the role of stress factors and seeding in inclusion body formation. 
While WT-7 mice with predominant affection of the ENS do not reflect characteristic 
pathological  and biochemical features of human TDP-43 proteinopathies, they will 
be valuable models to further investigate the function of TDP-43 and to identify 
dysregulated pathways upon transgene expression in neuron e.g. by proteomics and 
transcriptomics analysis of isolated ENS. Furthermore, they will allow to further 
address the influence of sex hormones on TDP-43 mediated toxicity. 
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